redhill biopharma ltd  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report redhill biopharma ltd  product pipeline review   published by global markets direct product code  published may   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license redhill biopharma ltd  product pipeline review   published may   content info  pages description summary global markets directs redhill biopharma ltd  product pipeline review   provides an overview of the redhill biopharma ltds pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of redhill biopharma ltds complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of redhill biopharma ltd including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of redhill biopharma ltds human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the redhill biopharma ltds pipeline products reasons to buy evaluate redhill biopharma ltds strategic position with total access to detailed information on its product pipeline assess the growth potential of redhill biopharma ltd in its therapy areas of focus identify new drug targets and therapeutic classes in the redhill biopharma ltds rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of redhill biopharma ltd and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of redhill biopharma ltd develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of redhill biopharma ltd and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures redhill biopharma ltd snapshot redhill biopharma ltd overview key information key facts redhill biopharma ltd  research and development overview key therapeutic areas redhill biopharma ltd  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities pipeline products  partnered products partnered productscombination treatment modalities redhill biopharma ltd  pipeline products glance redhill biopharma ltd  late stage pipeline products preregistration productscombination treatment modalities filing rejectedwithdrawn productscombination treatment modalities phase iii productscombination treatment modalities redhill biopharma ltd  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities redhill biopharma ltd  early stage pipeline products preclinical productscombination treatment modalities redhill biopharma ltd  drug profiles ondansetron hydrochloride cr product description mechanism of action rd progress rizatriptan benzoate product description mechanism of action rd progress rifabutin  amoxicillin sodium  omeprazole sodium product description mechanism of action rd progress rifabutin  clarithromycin  clofazimine product description mechanism of action rd progress carvedilol cr product description mechanism of action rd progress upamostat product description mechanism of action rd progress abc product description mechanism of action rd progress redhill biopharma ltd  pipeline analysis redhill biopharma ltd  pipeline products by target redhill biopharma ltd  pipeline products by route of administration redhill biopharma ltd  pipeline products by molecule type redhill biopharma ltd  pipeline products by mechanism of action redhill biopharma ltd  recent pipeline updates redhill biopharma ltd  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables redhill biopharma ltd key information redhill biopharma ltd key facts redhill biopharma ltd  pipeline by indication  redhill biopharma ltd  pipeline by stage of development  redhill biopharma ltd  monotherapy products in pipeline  redhill biopharma ltd  combination treatment modalities in pipeline  redhill biopharma ltd  partnered products in pipeline  redhill biopharma ltd  partnered products combination treatment modalities  redhill biopharma ltd  preregistration  redhill biopharma ltd  filing rejectedwithdrawn  redhill biopharma ltd  phase iii  redhill biopharma ltd  phase ii  redhill biopharma ltd  phase i  redhill biopharma ltd  preclinical  redhill biopharma ltd  pipeline by target  redhill biopharma ltd  pipeline by route of administration  redhill biopharma ltd  pipeline by molecule type  redhill biopharma ltd  pipeline products by mechanism of action  redhill biopharma ltd  recent pipeline updates  list of figures redhill biopharma ltd  pipeline by top  indication  redhill biopharma ltd  pipeline by stage of development  redhill biopharma ltd  monotherapy products in pipeline  redhill biopharma ltd  combination treatment modalities in pipeline  redhill biopharma ltd  partnered products in pipeline  redhill biopharma ltd  pipeline by top  target  redhill biopharma ltd  pipeline by top  route of administration  redhill biopharma ltd  pipeline by top  molecule type  redhill biopharma ltd  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved rdhl key statistics  redhill biopharma ltd adr financial ratios  marketwatch bulletin investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close redhill biopharma ltd adr nasdaq rdhl go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus redhill biopharma ltd adr market closed  quotes are delayed by  min jul    pm rdhl quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description redhill biopharma ltd is a biopharmaceutical company which is focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer the companys gastrointestinal p redhill biopharma ltd is a biopharmaceutical company which is focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer the companys gastrointestinal products include donnatal and enteragam its clinicalstage pipeline includes talicia rhb¸ bekinda rhb yeliva mesupron and rizaport the company was founded by dror benasher and ori shilo on august   and is headquartered in tel aviv israel valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title mr dror benasher   chairman  chief executive officer mr gilead raday   chief operating officer mr micha benchorin   chief financial officer dr reza fathi   senior vice presidentresearch  development dr terry f plasse   medical director insider actions – purchase – sale  – number of transactions  newslatestcompanyusrdhl marketwatch news on rdhl no news currently available for rdhl newsnonmarketwatchcompanyusrdhl other news on rdhl  smallcap biotechs to put on your radar  am july    seeking alpha redhill biopharmas rdhl ceo dror benasher on q  results  earnings call transcript  pm july    seeking alpha redhill bio q loss widens   am july    seeking alpha  things in biotech you should learn today july    am july    seeking alpha redhill updates on crohns candidate rhb second dsmb review later this month  am july    seeking alpha q biotech catalyst watch phase  data releases part   am july    seeking alpha bekinda phase iii guard study topline results  pm june    seeking alpha redhill biopharma rdhl presents at bio international conference   slideshow  pm june    seeking alpha redhill launches latestage study of h pylori killer rhb shares down  premarket on carryover from yesterdays reversal  am june    seeking alpha redhills bekinda successful in latestage gastroenteritis study shares ahead  premarket  am june    seeking alpha premarket gainers as of  am  am june    seeking alpha redhill bio launches two gi products in us shares up   pm june    seeking alpha biotech forum daily digest analysts warming to mylan spotlight on seres therapeutics  am may    seeking alpha redhill biopharma  biotech stock with upcoming catalysts  pm may    seeking alpha redhill biopharmas rdhl ceo dror benasher on q  results  earnings call transcript  pm may    seeking alpha redhills yeliva shows treatment effect in earlystage cancer study shares ahead  premarket  am april    seeking alpha redhill to host investor day april   am april    seeking alpha redhill nabs two new patents covering gi med bekinda  am april    seeking alpha  things in biotech you should learn today april    am april    seeking alpha intelgenx and redhill biopharma announce marketing approval of rizaport for migraines in luxembourg  am april    seeking alpha loading more headlines at a glance redhill biopharma ltd  haarbaa street tel aviv ta  phone   industry biotechnology sector health carelife sciences fiscal yearend  view sec filings revenue  net income m  sales growth  employees  annual report for rdhl newspressreleasecompanyusrdhl press releases on rdhl corporate news blog  fda grants fast track designation to flex pharmas flx for the treatment of severe muscle cramps associated with als  am july    accesswire redhill biopharma reports  second quarter financial results  am july    globe newswire redhill biopharma reports  second quarter financial results  am july    globenewswire redhill biopharma to host second quarter  financial results conference call on july    am july    globenewswire redhill biopharma announces last patient visit in bekindar phase ii study for ibsd  am july    globenewswire redhill biopharma announces last patient visit in bekindar phase ii study for ibsd  am july    globe newswire redhill biopharma announces expected timeline for dsmb meeting and provides update on enrollment in the rhb phase iii study for crohns disease  am july    globenewswire redhill biopharma announces expected timeline for dsmb meeting and provides update on enrollment in the rhb phase iii study for crohns disease  am july    globe newswire redhill biopharma to host conference call on successful phase iii topline results with bekindar for acute gastroenteritis  am june    globenewswire redhill biopharma announces confirmatory phase iii study initiated with rhb taliciatm for h pylori infection  am june    globe newswire redhill biopharma announces confirmatory phase iii study initiated with rhb taliciatm for h pylori infection  am june    globenewswire redhill biopharma announces successful phase iii topline results with bekindar for acute gastroenteritis  am june    globenewswire redhill biopharma announces successful phase iii topline results with bekindar for acute gastroenteritis  am june    globe newswire redhill biopharma initiates promotion of donnatalr and enteragamr in the us  am june    globe newswire redhill biopharma initiates promotion of donnatalr and enteragamr in the us  am june    globenewswire concordia international corp announces redhill biopharma has started promoting donnatalœ in the us  am june    pr newswire  prf redhill biopharma to present at the  bio international convention  am june    globenewswire redhill biopharma announces poster presentation of the positive rhb phase iii results for h pylori infection at digestive disease week   am may    globenewswire redhill biopharma reports  first quarter financial results  am may    globe newswire redhill biopharma reports  first quarter financial results  am may    globenewswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest amattel stock price target cut to  from  at da davidson astarbucks stock price target cut to  from  at instinet amastercard stock price target raised to  from  at instinet acan snap fall even more as lockups expire aa highpowered florida couple announces their ‘trump divorce’ averizon stock price target raised to  from  at instinet aamazon’s freespending ways hit earnings but don’t expect a shift to thrift aklatencor stock price target raised to  from  at instinet aus gdp speeds up to  in nd quarter ahot pie from ‘game of thrones’ is selling direwolf bread in real life aellie maes stock set for record selloff after results disappoints outlook slashed astock market set to extend fresh tech rout as amazon disappoints gdp data ahead aatlantic media selling ownership stake to organization run by laurene powell jobs aretail investors wait this long to dive into ipos amerck expects june cyberattack to affect companys  financial performance achevron swings to profit as charges shrink achevrons stock slips  premarket after q results amcconnell blames democrats after healthcare loss  house approves borderwall money achevron q revenue  bln vs  bln a year ago factset consensus  bln achevron q factset eps consensus  cents loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  about redhill  redhill menu about redhill company profile management team board of directors advisory board products commercial products donnatal® enteragam® development pipeline pipeline overview talicia™ h pylori rhb giinflammation crohns disease multiple sclerosis rheumatoid arthritis bekinda® gi gastroenteritis  gastritis ibsd rhb gi yeliva® oncology mesupron oncology rizaport® migraine expanded access program partnering investors news      contact careers homeabout redhill about redhill redhill biopharma ltd nasdaq rdhl telaviv stock exchange rdhl is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for the treatment of gastrointestinal and inflammatory diseases including cancer the company’s current product pipeline includes talicia™  an oral combination therapy for helicobacter pylori infection with positive results from a first phase iii study and an ongoing confirmatory phase iii study rhb  an oral combination therapy for the treatment of crohns disease with an ongoing first phase iii study a completed proofofconcept phase iia study for multiple sclerosis and qidp status for nontuberculous mycobacteria ntm infections bekinda® rhb  a oncedaily oral pill formulation of ondansetron with successful topline results from a phase iii study for acute gastroenteritis and gastritis and an ongoing phase ii study for ibsd rhb  an encapsulated formulation for bowel preparation licensed to salix pharmaceuticals ltd yeliva® abc  a phase iistage orallyadministered firstinclass sk selective inhibitor targeting multiple oncology inflammatory and gastrointestinal indications mesupron  a phase iistage orallyadministered firstinclass protease inhibitor targeting pancreatic cancer and other solid tumor cancers  rizaport® rhb  an oral thin film formulation of rizatriptan for the treatment of acute migraines with a us nda currently under discussion with the fda and marketing authorization received in germany in october  redhill promotes two gastrointestinal products in the us  donnatal® a prescription oral adjunctive drug used in the treatment of ibs and acute enterocolitis and enteragam® a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools company profile management team board of directors advisory board recent news  july  redhill biopharma reports  second quarter financial results  july  redhill biopharma to host second quarter  financial results conference call on july    july  redhill biopharma announces last patient visit in bekinda phase ii study for ibsd see all news   home  site map copyright   redhill all rights reserved created by catom web design  seo thank you for visiting redhills website at wwwredhillbiocom redhill site by clicking ok you acknowledge and understand that you will be linked outside of the redhill site and into other independent third party websites third party sites you further acknowledge and agree that we have no control over the third party sites nor over any content contained therein you further acknowledge that we are not responsible in any way for the availability suitability accuracy and completeness of any information or links contained in any of the third party sites nor do we endorse or are we responsible or liable for any services content advertisements products or any materials on or available from or through any of the third party sites in addition we urge you to carefully review each of the third party sites terms of service and privacy policies if such exist before visiting such third party sites ok rdhltel aviv stock quote  redhill biopharma ltd  bloomberg markets error could not add to watchlist x  watchlist redhill biopharma ltd rdhlit tel aviv ils   as of  am edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap m ils  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later  dgapnews redhill biopharma reports  second quarter financial results  redhill biopharma ltd redhill biopharma reports  second quarter financial results  redhill biopharma reports  second quarter financial results  redhill biopharma to host second quarter  financial results conference call on july    dgapnews redhill biopharma announces last patient visit in bekindar phase ii study for ibsd  redhill biopharma ltd redhill biopharma announces last patient visit in bekinda® phase ii study for ibsd  redhill biopharma announces last patient visit in bekinda® phase ii study for ibsd  dgapnews redhill biopharma announces expected timeline for dsmb meeting and provides updated on enrollment in the rhb pha  redhill biopharma ltd redhill biopharma announces expected timeline for dsmb meeting and provides update on enrollment in the  redhill biopharma announces expected timeline for dsmb meeting and provides update on enrollment in the rhb phase iii study there are currently no press releases for this ticker please check back later profile redhill biopharma ltd operates as a specialty biopharmaceutical company the company focuses on development and commercialization of late clinicalstage and proprietary small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer redhill biopharma promotes gastrointestinal products in the united states address  ha₣  arba₣  a streettel aviv israel phone  website wwwredhillbiocom executives board members dror benasher ceocofounder micha benchorin chief financial officer uri hananel aharon chief accounting officer gilead raday chief operating officer guy goldberg chief business officer show more redhill biopharma reports initial revenues in q as it grows raleigh ops  triangle business journal menu select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita limited time offer subscribe now search × close sign in sign in your account your account welcome your account sign in existing users create your free account dont have an account your account subscriptions newsletters custom notifications my custom site manage site users sign out sign in sign in your account search home industries  topics all industries  topics banking  financial services career  workplace commercial real estate education energy food  lifestyle government  regulations health care manufacturing media  marketing philanthropy  nonprofits professional services residential real estate retailing sports business technology transportation travel  tourism sponsored content smart moneysmart businesses  cre now we value your business office environments small business marketing know your neighborhood news news latest news business pulse press releases subscribers subscriberonly content digital edition start a subscription sign up for newsletters lists  awards lists all lists access the book of lists purchase the book of lists build your own lists submit your company to be on a list awards nominate for an award people  companies companies top private companies find businesses for sale search for company news people people on the move contact top executives executive profiles search for people in the news events events business event calendar nominations add your event event photos signature events bizwomen mentoring monday more… jobs find or post a job in raleighdurham store subscriptions reprints  more sales leads public records information to build your business how to grow your business advance your career home of the day premium real estate listings in raleighdurham bizspace best office spaces available in raleighdurham thought leadership trends tips and insights from our partners crane watch subscribers start a subscription subscriberonly content digital edition access the book of lists purchase the book of lists manage your account about  contact about us about the business journals advertise help  faqs contact us call center directory apps  syndication newsletters mobile apps syndicationrss acbj publications bizwomen upstart hemmings sports business journal inside lacrosse bostinno dcinno chicagoinno austininno select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita follow us twitter linkedin facebook google  please sign in and use this articles on page print button to print this article industry news health care redhill biopharma reports initial revenues in q as it grows raleigh ops jul   pm edt jennifer henderson staff writer triangle business journal jennifer henderson share order reprints save article print email facebook linkedin twitter save article more email facebook linkedin twitter save article jennifer henderson staff writer triangle business journal in this article health care dror benasher enlarge redhill biopharma is… more taylor mcdonald enlarge dror benasher named his company redhill after a hill in the community where he grew up… more taylor mcdonald redhill biopharma ltd nasdaq rdhl – which recently commenced commercial efforts and an ongoing expansion in raleigh following the recruitment of a number of former salix employees – has reported initial net revenues in the second quarter of  revenues of  were for the period between june  and june  following the start of us promotional activities for donnatal and sale of enteragam both gastrointestinal products according to redhill the company reported it had immaterial net revenues in the second quarter of last year and the first quarter of  enlarge dror benasher named his company redhill after a hill in the community where he grew up… more taylor mcdonald “our strategy is to become a revenue generating specialty gi pharma company with commercial presence in the us to set the stage for potential launch by redhill of our late clinical stage potential blockbuster gi products if approved by the fda” said redhill cofounder and ceo dror benasher on a company call reporting second quarter financial results july  “redhill remains focused on diligent execution and … implementation of exactly that strategy with several ongoing phase iii gi programs as well as the commencement last month of us specialty gi promotional activity with two commercial products” redhill reported research and development expenses of  million in the second quarter of  up  million from the second quarter of  primarily due to ongoing late state clinical studies for a number of products in development by the company and it reported general and administrative expenses of  million in the second quarter of  up  million from the second quarter of last year largely due to the establishment of us commercial operations the company also stated that it clocked selling and marketing expenses for the first time this year with selling marketing and business development expenses of  million in the second quarter operating loss was  million for the second quarter of  up  million from the second quarter of  as of june  redhill had cash and equivalents of  million “additional commercial gi products are planned to be added to the basket of our specialty gi us sales force later this year potentially utilizing and increasing economies of scale” said benasher home  redhill menu about redhill company profile management team board of directors advisory board products commercial products donnatal® enteragam® development pipeline pipeline overview talicia™ h pylori rhb giinflammation crohns disease multiple sclerosis rheumatoid arthritis bekinda® gi gastroenteritis  gastritis ibsd rhb gi yeliva® oncology mesupron oncology rizaport® migraine expanded access program partnering investors news      contact careers pipeline overview product planned indication preclinical phase iii phase iii ndamarketed gi  inflammation donnatal® ibs and acute enterocolitis us copromotion enteragam® chronic diarrhea and loose stools us exclusive license talicia™ rhb h pylori infections rhb crohns disease multiple sclerosis bekinda®rhb gastroenteritis  gastritis ibsd rhb bowel cleanser oncology  giinflammation yeliva® abc multiple indications mesupron pancreatic cancer other rizaport®rhb migraine  estimated timelineindication in the pipeline is subject to changes in development plans and regulatory requirementsclarifications including complementary additional studies  bekinda® yeliva® and rizaport® are proposed tradenames which are subject to fda review and approval  for full prescribing information see wwwdonnatalcom enteragam® is a medical food which must be administered under medical supervision company profileredhill biopharma nasdaq rdhl telaviv stock exchange rdhl is a specialty biopharmaceutical company focused primarily on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for the treatment of gastrointestinal and inflammatory diseases including cancer read more recent news  july  redhill biopharma reports  second quarter financial results  july  redhill biopharma to host second quarter  financial results conference call on july    july  redhill biopharma announces last patient visit in bekinda phase ii study for ibsd see all news home  site map copyright   redhill all rights reserved created by catom web design  seo thank you for visiting redhills website at wwwredhillbiocom redhill site by clicking ok you acknowledge and understand that you will be linked outside of the redhill site and into other independent third party websites third party sites you further acknowledge and agree that we have no control over the third party sites nor over any content contained therein you further acknowledge that we are not responsible in any way for the availability suitability accuracy and completeness of any information or links contained in any of the third party sites nor do we endorse or are we responsible or liable for any services content advertisements products or any materials on or available from or through any of the third party sites in addition we urge you to carefully review each of the third party sites terms of service and privacy policies if such exist before visiting such third party sites ok microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft redhill biopharma reports initial revenues in q as it grows raleigh ops  triangle business journal menu select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita limited time offer subscribe now search × close sign in sign in your account your account welcome your account sign in existing users create your free account dont have an account your account subscriptions newsletters custom notifications my custom site manage site users sign out sign in sign in your account search home industries  topics all industries  topics banking  financial services career  workplace commercial real estate education energy food  lifestyle government  regulations health care manufacturing media  marketing philanthropy  nonprofits professional services residential real estate retailing sports business technology transportation travel  tourism sponsored content smart moneysmart businesses  cre now we value your business office environments small business marketing know your neighborhood news news latest news business pulse press releases subscribers subscriberonly content digital edition start a subscription sign up for newsletters lists  awards lists all lists access the book of lists purchase the book of lists build your own lists submit your company to be on a list awards nominate for an award people  companies companies top private companies find businesses for sale search for company news people people on the move contact top executives executive profiles search for people in the news events events business event calendar nominations add your event event photos signature events bizwomen mentoring monday more… jobs find or post a job in raleighdurham store subscriptions reprints  more sales leads public records information to build your business how to grow your business advance your career home of the day premium real estate listings in raleighdurham bizspace best office spaces available in raleighdurham thought leadership trends tips and insights from our partners crane watch subscribers start a subscription subscriberonly content digital edition access the book of lists purchase the book of lists manage your account about  contact about us about the business journals advertise help  faqs contact us call center directory apps  syndication newsletters mobile apps syndicationrss acbj publications bizwomen upstart hemmings sports business journal inside lacrosse bostinno dcinno chicagoinno austininno select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita follow us twitter linkedin facebook google  please sign in and use this articles on page print button to print this article industry news health care redhill biopharma reports initial revenues in q as it grows raleigh ops jul   pm edt jennifer henderson staff writer triangle business journal jennifer henderson share order reprints save article print email facebook linkedin twitter save article more email facebook linkedin twitter save article jennifer henderson staff writer triangle business journal in this article health care dror benasher enlarge redhill biopharma is… more taylor mcdonald enlarge dror benasher named his company redhill after a hill in the community where he grew up… more taylor mcdonald redhill biopharma ltd nasdaq rdhl – which recently commenced commercial efforts and an ongoing expansion in raleigh following the recruitment of a number of former salix employees – has reported initial net revenues in the second quarter of  revenues of  were for the period between june  and june  following the start of us promotional activities for donnatal and sale of enteragam both gastrointestinal products according to redhill the company reported it had immaterial net revenues in the second quarter of last year and the first quarter of  enlarge dror benasher named his company redhill after a hill in the community where he grew up… more taylor mcdonald “our strategy is to become a revenue generating specialty gi pharma company with commercial presence in the us to set the stage for potential launch by redhill of our late clinical stage potential blockbuster gi products if approved by the fda” said redhill cofounder and ceo dror benasher on a company call reporting second quarter financial results july  “redhill remains focused on diligent execution and … implementation of exactly that strategy with several ongoing phase iii gi programs as well as the commencement last month of us specialty gi promotional activity with two commercial products” redhill reported research and development expenses of  million in the second quarter of  up  million from the second quarter of  primarily due to ongoing late state clinical studies for a number of products in development by the company and it reported general and administrative expenses of  million in the second quarter of  up  million from the second quarter of last year largely due to the establishment of us commercial operations the company also stated that it clocked selling and marketing expenses for the first time this year with selling marketing and business development expenses of  million in the second quarter operating loss was  million for the second quarter of  up  million from the second quarter of  as of june  redhill had cash and equivalents of  million “additional commercial gi products are planned to be added to the basket of our specialty gi us sales force later this year potentially utilizing and increasing economies of scale” said benasher home  redhill menu about redhill company profile management team board of directors advisory board products commercial products donnatal® enteragam® development pipeline pipeline overview talicia™ h pylori rhb giinflammation crohns disease multiple sclerosis rheumatoid arthritis bekinda® gi gastroenteritis  gastritis ibsd rhb gi yeliva® oncology mesupron oncology rizaport® migraine expanded access program partnering investors news      contact careers pipeline overview product planned indication preclinical phase iii phase iii ndamarketed gi  inflammation donnatal® ibs and acute enterocolitis us copromotion enteragam® chronic diarrhea and loose stools us exclusive license talicia™ rhb h pylori infections rhb crohns disease multiple sclerosis bekinda®rhb gastroenteritis  gastritis ibsd rhb bowel cleanser oncology  giinflammation yeliva® abc multiple indications mesupron pancreatic cancer other rizaport®rhb migraine  estimated timelineindication in the pipeline is subject to changes in development plans and regulatory requirementsclarifications including complementary additional studies  bekinda® yeliva® and rizaport® are proposed tradenames which are subject to fda review and approval  for full prescribing information see wwwdonnatalcom enteragam® is a medical food which must be administered under medical supervision company profileredhill biopharma nasdaq rdhl telaviv stock exchange rdhl is a specialty biopharmaceutical company focused primarily on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for the treatment of gastrointestinal and inflammatory diseases including cancer read more recent news  july  redhill biopharma reports  second quarter financial results  july  redhill biopharma to host second quarter  financial results conference call on july    july  redhill biopharma announces last patient visit in bekinda phase ii study for ibsd see all news home  site map copyright   redhill all rights reserved created by catom web design  seo thank you for visiting redhills website at wwwredhillbiocom redhill site by clicking ok you acknowledge and understand that you will be linked outside of the redhill site and into other independent third party websites third party sites you further acknowledge and agree that we have no control over the third party sites nor over any content contained therein you further acknowledge that we are not responsible in any way for the availability suitability accuracy and completeness of any information or links contained in any of the third party sites nor do we endorse or are we responsible or liable for any services content advertisements products or any materials on or available from or through any of the third party sites in addition we urge you to carefully review each of the third party sites terms of service and privacy policies if such exist before visiting such third party sites ok home  redhill menu about redhill company profile management team board of directors advisory board products commercial products donnatal® enteragam® development pipeline pipeline overview talicia™ h pylori rhb giinflammation crohns disease multiple sclerosis rheumatoid arthritis bekinda® gi gastroenteritis  gastritis ibsd rhb gi yeliva® oncology mesupron oncology rizaport® migraine expanded access program partnering investors news      contact careers pipeline overview product planned indication preclinical phase iii phase iii ndamarketed gi  inflammation donnatal® ibs and acute enterocolitis us copromotion enteragam® chronic diarrhea and loose stools us exclusive license talicia™ rhb h pylori infections rhb crohns disease multiple sclerosis bekinda®rhb gastroenteritis  gastritis ibsd rhb bowel cleanser oncology  giinflammation yeliva® abc multiple indications mesupron pancreatic cancer other rizaport®rhb migraine  estimated timelineindication in the pipeline is subject to changes in development plans and regulatory requirementsclarifications including complementary additional studies  bekinda® yeliva® and rizaport® are proposed tradenames which are subject to fda review and approval  for full prescribing information see wwwdonnatalcom enteragam® is a medical food which must be administered under medical supervision company profileredhill biopharma nasdaq rdhl telaviv stock exchange rdhl is a specialty biopharmaceutical company focused primarily on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for the treatment of gastrointestinal and inflammatory diseases including cancer read more recent news  july  redhill biopharma reports  second quarter financial results  july  redhill biopharma to host second quarter  financial results conference call on july    july  redhill biopharma announces last patient visit in bekinda phase ii study for ibsd see all news home  site map copyright   redhill all rights reserved created by catom web design  seo thank you for visiting redhills website at wwwredhillbiocom redhill site by clicking ok you acknowledge and understand that you will be linked outside of the redhill site and into other independent third party websites third party sites you further acknowledge and agree that we have no control over the third party sites nor over any content contained therein you further acknowledge that we are not responsible in any way for the availability suitability accuracy and completeness of any information or links contained in any of the third party sites nor do we endorse or are we responsible or liable for any services content advertisements products or any materials on or available from or through any of the third party sites in addition we urge you to carefully review each of the third party sites terms of service and privacy policies if such exist before visiting such third party sites ok redhill biopharma ltd  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports redhill biopharma ltd  product pipeline review   redhill biopharma ltd  product pipeline review   wgr  may  global  pages global markets direct description table of content sample report enquiry before buy related reports redhill biopharma ltd  product pipeline review  summaryglobal markets direct’s ‘redhill biopharma ltd  product pipeline review  ’ provides an overview of the redhill biopharma ltd’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of redhill biopharma ltd’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of redhill biopharma ltd including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of redhill biopharma ltd’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the redhill biopharma ltd’s pipeline productsreasons to buy evaluate redhill biopharma ltd’s strategic position with total access to detailed information on its product pipeline assess the growth potential of redhill biopharma ltd in its therapy areas of focus identify new drug targets and therapeutic classes in the redhill biopharma ltd’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of redhill biopharma ltd and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of redhill biopharma ltd develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of redhill biopharma ltd and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures redhill biopharma ltd snapshot redhill biopharma ltd overview key information key facts redhill biopharma ltd  research and development overview key therapeutic areas redhill biopharma ltd  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities pipeline products  partnered products partnered productscombination treatment modalities redhill biopharma ltd  pipeline products glance redhill biopharma ltd  late stage pipeline products preregistration productscombination treatment modalities filing rejectedwithdrawn productscombination treatment modalities phase iii productscombination treatment modalities redhill biopharma ltd  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities redhill biopharma ltd  early stage pipeline products preclinical productscombination treatment modalities redhill biopharma ltd  drug profiles ondansetron hydrochloride cr product description mechanism of action rd progress rizatriptan benzoate product description mechanism of action rd progress rifabutin  amoxicillin sodium  omeprazole sodium product description mechanism of action rd progress rifabutin  clarithromycin  clofazimine product description mechanism of action rd progress carvedilol cr product description mechanism of action rd progress upamostat product description mechanism of action rd progress abc product description mechanism of action rd progress redhill biopharma ltd  pipeline analysis redhill biopharma ltd  pipeline products by target redhill biopharma ltd  pipeline products by route of administration redhill biopharma ltd  pipeline products by molecule type redhill biopharma ltd  pipeline products by mechanism of action redhill biopharma ltd  recent pipeline updates redhill biopharma ltd  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesredhill biopharma ltd key information redhill biopharma ltd key facts redhill biopharma ltd  pipeline by indication  redhill biopharma ltd  pipeline by stage of development  redhill biopharma ltd  monotherapy products in pipeline  redhill biopharma ltd  combination treatment modalities in pipeline  redhill biopharma ltd  partnered products in pipeline  redhill biopharma ltd  partnered products combination treatment modalities  redhill biopharma ltd  preregistration  redhill biopharma ltd  filing rejectedwithdrawn  redhill biopharma ltd  phase iii  redhill biopharma ltd  phase ii  redhill biopharma ltd  phase i  redhill biopharma ltd  preclinical  redhill biopharma ltd  pipeline by target  redhill biopharma ltd  pipeline by route of administration  redhill biopharma ltd  pipeline by molecule type  redhill biopharma ltd  pipeline products by mechanism of action  redhill biopharma ltd  recent pipeline updates  list of figuresredhill biopharma ltd  pipeline by top  indication  redhill biopharma ltd  pipeline by stage of development  redhill biopharma ltd  monotherapy products in pipeline  redhill biopharma ltd  combination treatment modalities in pipeline  redhill biopharma ltd  partnered products in pipeline  redhill biopharma ltd  pipeline by top  target  redhill biopharma ltd  pipeline by top  route of administration  redhill biopharma ltd  pipeline by top  molecule type  redhill biopharma ltd  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send home  redhill menu about redhill company profile management team board of directors advisory board products commercial products donnatal® enteragam® development pipeline pipeline overview talicia™ h pylori rhb giinflammation crohns disease multiple sclerosis rheumatoid arthritis bekinda® gi gastroenteritis  gastritis ibsd rhb gi yeliva® oncology mesupron oncology rizaport® migraine expanded access program partnering investors news      contact careers pipeline overview product planned indication preclinical phase iii phase iii ndamarketed gi  inflammation donnatal® ibs and acute enterocolitis us copromotion enteragam® chronic diarrhea and loose stools us exclusive license talicia™ rhb h pylori infections rhb crohns disease multiple sclerosis bekinda®rhb gastroenteritis  gastritis ibsd rhb bowel cleanser oncology  giinflammation yeliva® abc multiple indications mesupron pancreatic cancer other rizaport®rhb migraine  estimated timelineindication in the pipeline is subject to changes in development plans and regulatory requirementsclarifications including complementary additional studies  bekinda® yeliva® and rizaport® are proposed tradenames which are subject to fda review and approval  for full prescribing information see wwwdonnatalcom enteragam® is a medical food which must be administered under medical supervision company profileredhill biopharma nasdaq rdhl telaviv stock exchange rdhl is a specialty biopharmaceutical company focused primarily on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for the treatment of gastrointestinal and inflammatory diseases including cancer read more recent news  july  redhill biopharma reports  second quarter financial results  july  redhill biopharma to host second quarter  financial results conference call on july    july  redhill biopharma announces last patient visit in bekinda phase ii study for ibsd see all news home  site map copyright   redhill all rights reserved created by catom web design  seo thank you for visiting redhills website at wwwredhillbiocom redhill site by clicking ok you acknowledge and understand that you will be linked outside of the redhill site and into other independent third party websites third party sites you further acknowledge and agree that we have no control over the third party sites nor over any content contained therein you further acknowledge that we are not responsible in any way for the availability suitability accuracy and completeness of any information or links contained in any of the third party sites nor do we endorse or are we responsible or liable for any services content advertisements products or any materials on or available from or through any of the third party sites in addition we urge you to carefully review each of the third party sites terms of service and privacy policies if such exist before visiting such third party sites ok home  redhill menu about redhill company profile management team board of directors advisory board products commercial products donnatal® enteragam® development pipeline pipeline overview talicia™ h pylori rhb giinflammation crohns disease multiple sclerosis rheumatoid arthritis bekinda® gi gastroenteritis  gastritis ibsd rhb gi yeliva® oncology mesupron oncology rizaport® migraine expanded access program partnering investors news      contact careers pipeline overview product planned indication preclinical phase iii phase iii ndamarketed gi  inflammation donnatal® ibs and acute enterocolitis us copromotion enteragam® chronic diarrhea and loose stools us exclusive license talicia™ rhb h pylori infections rhb crohns disease multiple sclerosis bekinda®rhb gastroenteritis  gastritis ibsd rhb bowel cleanser oncology  giinflammation yeliva® abc multiple indications mesupron pancreatic cancer other rizaport®rhb migraine  estimated timelineindication in the pipeline is subject to changes in development plans and regulatory requirementsclarifications including complementary additional studies  bekinda® yeliva® and rizaport® are proposed tradenames which are subject to fda review and approval  for full prescribing information see wwwdonnatalcom enteragam® is a medical food which must be administered under medical supervision company profileredhill biopharma nasdaq rdhl telaviv stock exchange rdhl is a specialty biopharmaceutical company focused primarily on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for the treatment of gastrointestinal and inflammatory diseases including cancer read more recent news  july  redhill biopharma reports  second quarter financial results  july  redhill biopharma to host second quarter  financial results conference call on july    july  redhill biopharma announces last patient visit in bekinda phase ii study for ibsd see all news home  site map copyright   redhill all rights reserved created by catom web design  seo thank you for visiting redhills website at wwwredhillbiocom redhill site by clicking ok you acknowledge and understand that you will be linked outside of the redhill site and into other independent third party websites third party sites you further acknowledge and agree that we have no control over the third party sites nor over any content contained therein you further acknowledge that we are not responsible in any way for the availability suitability accuracy and completeness of any information or links contained in any of the third party sites nor do we endorse or are we responsible or liable for any services content advertisements products or any materials on or available from or through any of the third party sites in addition we urge you to carefully review each of the third party sites terms of service and privacy policies if such exist before visiting such third party sites ok as redhill biopharma ltd trades do analysts recommend you sell  the de soto edge ftse    nasdaq composite  na sp   na nikkei    hang seng index    the de soto edge the de soto edge news online in the news fortune brands home  security inc nysefbhs receives an update from brokers flagstar bancorp inc nysefbc receives an update from brokers in volatile markets do analysts think you should buy facebook inc nasdaqfb as fate therapeutics inc trades do analysts recommend you sell as fastenal company trades do analysts recommend you sell facebook twitter youtube instagram pinterest as redhill biopharma ltd trades do analysts recommend you sell by ashley brown  in stocks  on wednesday  jul   am   comments as redhill biopharma ltd trades currently  analysts have their eyes on the stock whilst  of which rate it “buy”  “outperform”  “underperform”  “sell” while  “hold” individual stock ratings issued for rdhl are highlighted below  – broker fbr capital markets rating new target  reiteration  – broker ascendiant capital markets rating new target  reiteration  – broker nomura rating new target  reiteration  – broker northland securities rating new target  newcoverage  – broker hc wainwright rating new target  reiteration  – broker roth capital rating new target  reiteration  – broker mlv  co rating new target  reiteration  – broker zacks rating new target  upgrade the average target price given to the stock from the most recent broker reports is  the stock increased   during the last days session reaching  and roughly  shares were bought or sold by traders redhill biopharma ltd is an israelbased specialty biopharmaceutical company the company focuses on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer it offers the following gastrointestinal products in the united states donnatal a prescription oral adjunctive drug used in the treatment of irritable bowel syndrome ibs and acute enterocolitis as well as enteragam a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools its clinicalstage pipeline includes talicia rhb an oral combination therapy for the treatment of helicobacter pylori infection rhb an oral combination therapy for the treatment of crohn’s disease bekinda rhb a oncedaily oral pill formulation of ondansetron rhb yeliva abc mesupron and rizaport rhb more from reuters » receive redhill biopharma ltd news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for redhill biopharma ltd with marketbeatcoms free daily email newsletter recommended posts fortune brands home  security inc nysefbhs receives an update from brokers analysts reviewing fortune brands home  security inc have recently updated their recommended buysell flagstar bancorp inc nysefbc receives an update from brokers analysts reviewing flagstar bancorp inc have recently updated their recommended buysell ratings and in volatile markets do analysts think you should buy facebook inc nasdaqfb following us election volatility some analysts have updated their recommended target prices on shares as fate therapeutics inc trades do analysts recommend you sell as fate therapeutics inc trades currently  analysts have their eyes on the stock whilst  of which free email newsletter enter your email address below to get the latest news and analysts ratings for your stocks with marketbeats free daily email newsletter press releases  redhill biopharma ltd menu about redhill company profile management team board of directors advisory board products commercial products donnatal® enteragam® development pipeline pipeline overview talicia™ h pylori rhb giinflammation crohns disease multiple sclerosis rheumatoid arthritis bekinda® gi gastroenteritis  gastritis ibsd rhb gi yeliva® oncology mesupron oncology rizaport® migraine expanded access program partnering investors press releases events  webcasts sec filings and financial information stock information analyst information corporate governance contact us news      contact careers homeinvestors press releases press releases year all years          sort by date descending date ascending update   press releases   date summary view jul   redhill biopharma reports  second quarter financial results redhill maintains a debtfree balance sheet with  million cash at the end of the second quarter of   select recent milestones include initial net revenues of approximately  million between june  following commencement of promotional activities in the us by redhills gifocused sales force with two gi specialty products do pdf jul   redhill biopharma to host second quarter  financial results conference call on july   telaviv israel and raleigh nc july   globe newswire  redhill biopharma ltd nasdaqrdhl telaviv stock exchangerdhl redhill or the company a specialty biopharmaceutical company primarily focused on late clinicalstage development and commercialization of proprietary orallyadministered small molecule drugs for gastr pdf jul   redhill biopharma announces last patient visit in bekinda® phase ii study for ibsd topline results are expected in september  the randomized doubleblind placebocontrolled phase ii study is evaluating the safety and efficacy of bekinda® rhb  mg in  us patients with diarrheapredominant irritable bowel syndrome ibsd with a primary endpoint of response in stool consistency as compared to baseline ibs  pdf jul   redhill biopharma announces expected timeline for dsmb meeting and provides update on enrollment in the rhb phase iii study for crohns disease the second independent data and safety monitoring board dsmb meeting of the rhb phase iii study for crohns disease map us study is planned to be held in late july  and will assess the safety and efficacy of rhb in the first  subjects who have completed week  assessmentsthe dsmb meeting will include an interim efficacy analysis pdf jun   redhill biopharma to host conference call on successful phase iii topline results with bekinda® for acute gastroenteritis telaviv israel and raleigh nc june   globe newswire  redhill biopharma ltd nasdaqrdhl telaviv stock exchangerdhl redhill or the company a specialty biopharmaceutical company primarily focused on late clinicalstage development and commercialization of proprietary orallyadministered small molecule drugs for gastr pdf jun   redhill biopharma announces confirmatory phase iii study initiated with rhb taliciatm for h pylori infection subject to a successful outcome and any additional regulatory feedback the confirmatory phase iii study eradicate hp  is expected to complete the package required for a potential us nda for rhb newly branded as taliciatm   the twoarm randomized doubleblind active comparator confirmatory phase iii study is planned to enroll  no pdf jun   redhill biopharma announces confirmatory phase iii study initiated with rhb talicia™ for h pylori infection subject to a successful outcome and any additional regulatory feedback the confirmatory phase iii study eradicate hp  is expected to complete the package required for a potential us nda for rhb newly branded as talicia™  the twoarm randomized doubleblind active comparator confirmatory phase iii study is planned to enroll   pdf jun   redhill biopharma announces successful phase iii topline results with bekinda® for acute gastroenteritis the positive phase iii topline results indicate that the study successfully met its primary endpoint and bekinda®  mg was shown to be effective safe and well tolerated in patients with acute gastroenteritis and gastritis redhill will host a conference call and webcast to discuss the topline results from the bekinda® phase iii study  pdf jun   redhill biopharma initiates promotion of donnatal® and enteragam® in the us redhill has initiated commercial activities in the us with its gastrointestinalfocused sales force promoting two gastrointestinal specialty products donnatal® and enteragam® telaviv israel and raleigh nc june   globe newswire  redhill biopharma ltd nasdaqrdhl telaviv stock exchangerdhl redhill or the com pdf jun   redhill biopharma to present at the  bio international convention telaviv israel june   globe newswire  redhill biopharma ltd nasdaqrdhl telaviv stock exchangerdhl redhill or the company a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal a pdf may   redhill biopharma announces poster presentation of the positive rhb phase iii results for h pylori infection at digestive disease week  telaviv israel may   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory dise pdf may   redhill biopharma reports  first quarter financial results redhill maintains a debtfree balance sheet with a  million cash balance at the end of the first quarter of  allowing the company to continue to diligently execute its development and us commercialization plansselect recent milestones include exclusive us copromotion agreement for commercial gi drug donnatal® exclusive licen pdf apr   redhill biopharma to host first quarter  financial results conference call on may   telaviv israel april   globe newswire  redhill biopharma ltd nasdaqrdhl telaviv stock exchangerdhl redhill or the company a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal  pdf apr   redhill biopharma announces enrollment of last patient in the bekinda® phase ii study for ibsd topline results are expected in the third quarter of   the randomized doubleblind placebocontrolled phase ii study is evaluating the safety and efficacy of bekinda® rhb  mg in  us patients with diarrheapredominant irritable bowel syndrome ibsd ibs is one of the most common gastrointestinal disorders it is estimated t pdf apr   redhill biopharma announces peerreviewed publication of the positive yeliva® phase i study results in advanced solid tumors the article was authored by scientists from the medical university of south carolina musc hollings cancer center and apogee biotechnology and was published in clinical cancer researchthe phase i study with yeliva® in patients with advanced solid tumors successfully met its primary and secondary endpointsresults demonstrated that the drug is  pdf apr   redhill biopharma to host rd day on bekinda® for acute gastroenteritis and ibsd the rd day on bekinda® will take place on thursday april   in nyc from  edt a live webcast will be available through redhills websitetopline results from a phase iii study with bekinda®  mg for acute gastroenteritis and gastritis are expected in qtopline results from a phase ii study with bekinda®  mg pdf apr   redhill biopharma receives notice of allowance for two additional us patents covering bekinda® redhill received notices of allowance from the united states patent and trademark office uspto for two new patents covering bekinda® rhb expected to be valid until at least  once granted bekinda® is a proprietary bimodal extendedrelease oncedaily oral pill formulation of ondansetron targeting several gastrointestinal in pdf apr   redhill biopharma and intelgenx announce marketing approval of rizaport® for migraines in luxembourg the national marketing approval in luxembourg completes the current approval process of rizaport® under the european decentralized procedure dcp rizaport® is also approved for marketing in germany and a national marketing authorization application maa has been submitted in spainrizaport® is a proprietary oral thin film formulati pdf apr   redhill biopharma announces exclusive us license from entera health for commercial gi product enteragam® redhill expects to initiate us promotion of its two commerciallyavailable gastrointestinal specialty products donnatal® and enteragam® in mid under the terms of the agreement redhill will pay entera health royalties on net sales generated from the sale of enteragam® by redhill telaviv israel april   globe new pdf apr   redhill biopharma receives fda orphan drug designation for yeliva® for the treatment of cholangiocarcinoma orphan drug designation allows redhill to benefit from various development incentives to develop yeliva® abc for cholangiocarcinoma as well as a sevenyear marketing exclusivity period for the indication if approved for marketing a phase iia clinical study with yeliva® in patients with advanced unresectable intrahepatic and ex pdf mar   redhill biopharma to present at biocentury future leaders in the biotech industry conference telaviv israel march   globe newswire  redhill biopharma ltd nasdaqrdhl telaviv stock exchangerdhl redhill or the company a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal  pdf mar   redhill biopharma to present at the  map conference telaviv israel march   globe newswire  redhill biopharma ltd nasdaqrdhl telaviv stock exchangerdhl redhill or the company a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal  pdf mar   redhill biopharma announces first patient dosed in the openlabel extension study to the phase iii study with rhb for crohns disease a first randomized doubleblind placebocontrolled phase iii clinical study with rhb for the treatment of crohns disease the map us study is ongoing in the us and additional countries the openlabel extension study the map us study is intended to assess the safety and efficacy of rhb in patients who have completed  weeks of trea pdf mar   redhill biopharma to present at the bioeurope spring  conference telaviv israel march   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory di pdf mar   redhill biopharmas copromotion partner concordia announces us district court grants treble damages relating to donnatal® redhill and concordia recently entered into an exclusive copromotion agreement granting redhill certain promotion rights in the us for donnatal®redhill expects to initiate promotion of donnatal® in the second quarter of telaviv israel march   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhil pdf feb   redhill biopharma announces availability of its annual report on form f through its website telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory dis pdf feb   redhill biopharma reports  fourth quarter and fullyear financial results redhill maintains a strong and debtfree balance sheet with approximately  million in cash and cash equivalents at the end of  allowing the company to continue to execute its development and us commercialization plans select  milestones include successful final results from the first phase iii study with rhb for the treatme pdf feb   redhill biopharma completes treatment of last patient in bekinda® phase iii study for acute gastroenteritis topline results are expected in the second quarter of   the randomized doubleblind placebocontrolled phase iii study is evaluating the safety and efficacy of bekinda®  mg in patients with acute gastroenteritis and gastritis the guard study acute gastroenteritis and gastritis are inflammations of the mucus membranes of the gastroin pdf feb   redhill biopharma to host fourth quarter and fullyear  financial results conference call on february   telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory dis pdf feb   redhill biopharma announces enrollment of last patient in bekinda® phase iii study for acute gastroenteritis topline results are expected in the second quarter of  the randomized doubleblind placebocontrolled phase iii study is evaluating the safety and efficacy of bekinda® mg in patients with acute gastroenteritis and gastritis the guard study acute gastroenteritis and gastritis are inflammations of the mucus membranes of the gast pdf feb   redhill biopharma to present at the bio ceo  investor conference telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory dis pdf jan   redhill biopharma provides  semiannual business update telaviv israel jan   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory disea pdf jan   redhill biopharma announces qidp fasttrack designation granted by fda to rhb for nontuberculous mycobacteria infections rhb has been granted qualified infectious disease product qidp designation by the us fda for the treatment of nontuberculous mycobacteria ntm infection     under fdas generating antibiotic incentives now gain act qidp designation allows for fasttrack status and priority review potentially leading to a shorter nda review time by th pdf jan   redhill biopharma announces first dosing in rhb supportive pk studies ahead of confirmatory phase iii study for h pylori infection the first group of subjects have been dosed in a singledose threeway crossover pharmacokinetic pk study with rhb versus the active comparators in the confirmatory phase iii study and in a foodeffect study with rhb in healthy volunteersthe confirmatory phase iii study with rhb for h pylori infection is planned to be initiated subj pdf jan   redhill biopharmas rhb positive phase iii study results for h pylori infection presented at the innovations in gastroenterology  symposium telaviv israel jan   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory dis pdf jan   redhill biopharma announces exercise of stock options by directors and senior management members of redhills board of directors senior management and advisory board have exercised stock options to purchase an aggregate of  ordinary shares equivalent to  american depositary shares adss during the last weekfollowing issuance of the ordinary shares underlying these stock options the total number of outstanding ordin pdf jan   redhill biopharma announces yeliva® abc abstract presentation at the  cholangiocarcinoma foundation annual conference the abstract to be presented at the upcoming  cholangiocarcinoma foundation annual conference describes positive findings from nonclinical studies and the phase i clinical study with yeliva® abc suggesting that yeliva® may be an effective drug for the treatment of cholangiocarcinoma a phase i study with yeliva® in pa pdf jan   redhill biopharma announces new research collaboration with aarhus university for oncology drug mesupron the new research collaboration follows previous nonclinical studies conducted with denmarks aarhus university and is designed to identify additional high affinity molecular targets of mesupron upamostatfurther evaluation of mesupron together with aarhus university may allow for selection of appropriate sub populations of patients toward demon pdf jan   redhill biopharma to present the positive results of the first phase iii study with rhb for h pylori infection at the innovations in gastroenterology  symposium telaviv israel jan   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory dis pdf jan   redhill biopharma announces exercise of underwriters option telaviv israel jan   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory dis pdf jan   redhill biopharma announces exclusive us copromotion agreement with concordia for gi drug donnatal® redhill and concordia entered into an exclusive copromotion agreement granting redhill certain us promotion rights for donnatal®donnatal® tablets and elixir syrup is a prescription oral drug used with other drugs for the treatment of irritable bowel syndrome ibs and acute enterocolitis inflammation of the small bowelunder the pdf dec   redhill biopharma to present at the biotech showcase  telaviv israel dec   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and canc pdf dec   redhill biopharma announces closing of concurrent public offering and registered direct offering of its american depositary shares and warrants and partial exercise of the option of underwriters telaviv israel dec   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and  pdf dec   redhill biopharma prices concurrent public offering and registered direct offering of its american depositary shares and warrants  telaviv israel dec   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and  pdf dec   redhill biopharma announces proposed concurrent public offering and registered direct offering of its american depositary shares and warrants telaviv israel dec   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and  pdf dec   redhill biopharma announces first patient dosed in phase ibii study with yeliva® for multiple myeloma the first patients have been screened and a first patient has been dosed in the openlabel dose escalation phase ibii study with yeliva® abc for multiple myelomathe phase ibii clinical study is intended to evaluate the safety and efficacy of yeliva® in up to  patients with refractory or relapsed multiple myeloma who have prev pdf dec   redhill biopharma and intelgenx announce definitive agreement for commercialization of rizaport® for migraines with pharmatronic co in south korea redhill and its codevelopment partner intelgenx corp intelgenx have signed a definitive agreement with pharmatronic co granting an exclusive license to commercialize the acute migraine drug rizaport® in south korea this agreement follows the previously announced commercialization agreement with grupo juste saqf for spain and the  pdf dec   redhill biopharma announces positive and unanimous dsmb recommendation for continuation of phase iii study with rhb for crohns disease following a preplanned review of safety data redhill has received a unanimous recommendation from the independent data and safety monitoring board dsmb to continue the map us phase iii study with rhb for crohns disease as planned without any modificationsa second dsmb meeting expected in q will include an interim efficacy analysis pdf dec   redhill biopharma announces phase iia week final results further supporting potential of rhb in multiple sclerosis thought to be autoimmune in nature the multiple sclerosis ms inflammatory process is also consistent with an infectious disease the ceasems phase iia proofofconcept poc singlearm openlabel study was designed with a series of exploratory endpoints to evaluate the safety and potential efficacy of fixed oraldose rhb as an addon ther pdf dec   redhill biopharma to present at the jefferies microbiome summit telaviv israel dec   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and canc pdf nov   redhill biopharma announces yeliva™ abc poster presentation at the  eortcnciaacr molecular targets and cancer therapeutics symposium the poster to be presented at the upcoming eortcnciaacr molecular targets and cancer therapeutics symposium describes results from nonclinical studies conducted by apogee biotechnology corp demonstrating the potential antitumor and antiinflammatory effects of yeliva™ abc in combination with radiation yeliva™ is a proprie pdf nov   redhill biopharma to present at the german equity forum  telaviv israel nov   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and canc pdf nov   redhill biopharma reports  third quarter financial results redhill maintains a debtfree balance sheet with  million in cash at the end of the third quarter allowing the company to continue to diligently execute its three ongoing phase iii gastrointestinal disease programs and other clinicalstage programs recent key milestones include enhancement of the rhb phase iii crohns disease program i pdf nov   redhill biopharma reports positive fda type b meeting on rhb for h pylori infection ahead of confirmatory phase iii study the confirmatory phase iii study with rhb for h pylori infection is planned to be initiated in h after completion of the ongoing supportive pk program subject to a successful outcome the confirmatory phase iii study and the supportive pk program are expected to complete the package required for a us nda for rhb including clinic pdf nov   redhill biopharma to host third quarter  financial results conference call on november   telaviv israel nov   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases includi pdf nov   redhill biopharma to present at the jefferies  london healthcare conference telaviv israel nov   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and canc pdf nov   redhill biopharma provides update on ongoing phase iii and phase ii studies with bekinda® and expected timing of topline results topline results from both the ongoing phase iii clinical study for acute gastroenteritis and gastritis and the ongoing phase ii clinical study for diarrheapredominant irritable bowel syndrome ibsd are expected in mid   over twothirds of the planned total of  subjects have been enrolled to date in the phase iii clinical study with beki pdf nov   redhill biopharma announces withdrawal of public offering of its american depositary shares telaviv israel nov   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and  pdf nov   redhill biopharma to host investor conference call today at  edt following announcement of proposed public offering of its american depository shares telaviv israel nov   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and  pdf nov   redhill biopharma announces proposed public offering of its american depository shares telaviv israel nov   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and ca pdf oct   redhill biopharma to present at the bioeurope  conference telaviv israel oct   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and canc pdf oct   redhill biopharma announces allowance of a patent in japan supporting rhb for multiple sclerosis redhill has received from the japan patent office a notice of allowance for a new patent covering rhb for multiple sclerosis ms expected to be valid until  once granted redhills robust rhb patent portfolio covering its oral antibiotic combination therapy includes more than  patents in many countries including the us australia pdf oct   redhill biopharma to present at the bio investor forum  telaviv israel oct   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and canc pdf oct   redhill biopharma to host webcast today at  am edt following announcement of progress update on rhb phase iii crohns disease program including the introduction of an option for early stop for success in q telaviv israel oct   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and canc pdf oct   redhill biopharma provides progress update on rhb phase iii crohns disease program and introduces option for early stop for success in q an option for early stop for success for overwhelming efficacy has been introduced into the ongoing first phase iii study with rhb for crohns disease the map us study and analysis is expected in the second quarter of  as part of a second independent data safety and monitoring board dsmb interim safety and efficacy review the introdu pdf oct   redhill biopharma announces initiation of phase ii study with yeliva™ in hepatocellular carcinoma at the medical university of south carolina the phase ii clinical study is intended to evaluate the efficacy and safety of yeliva™ abc in patients with advanced hepatocellular carcinoma hcc the most common primary malignant cancer of the liver with a worldwide mortality rate of the phase ii study is being conducted at the hollings cancer center at the medical university o pdf sep   redhill biopharma to present at the bionetwork west  partnering summit telaviv israel sept   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and can pdf sep   redhill biopharma and intelgenx announce rizaport® commercialization term sheet with pharmatronic co for korea rizaport®  mg and  mg was granted marketing approval in germany under the european decentralized procedure dcpthis binding term sheet for the license of rizaport® in south korea follows a recent commercialization agreement for spain with grupo juste saqf who recently filed a national marketing authorization application maa fo pdf sep   redhill biopharma announces research collaboration with stanford university for yeliva™ telaviv israel sept   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and can pdf sep   redhill biopharma announces phase ibii study with yeliva™ initiated for multiple myeloma at a leading us academic medical center the phase ibii clinical study is intended to evaluate the safety and efficacy of yeliva™ abc in patients with refractory or relapsed multiple myeloma and is supported by a  million grant from the national cancer institute nci awarded to apogee biotechnology corp with additional support from redhill yeliva™ is a proprieta pdf sep   redhill biopharma to present at the th annual biopharm america international partnering conference telaviv israel sept   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and can pdf aug   redhill biopharma to present at the rodman  renshaw th annual global investment conference telaviv israel aug   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and canc pdf aug   redhill biopharma announces approval of a european patent supporting rhb for multiple sclerosis redhill has received from the european patent office a notice of intention to grant a new patent covering rhb for multiple sclerosis ms expected to be valid until  once granted a phase iia proofofconcept study evaluating rhb in patients treated for relapsingremitting multiple sclerosis is ongoing the ceasems study with topli pdf aug   redhill biopharma provides  semiannual rd update telaviv israel aug   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal and inflammatory diseases and canc pdf aug   redhill biopharma announces last patient visit in phase iia study with rhb for multiple sclerosis the phase iia proofofconcept study evaluates the safety and potential efficacy of fixed oral dose rhb as an addon therapy to interferon betaa for relapsingremitting multiple sclerosis rrms analysis of the study is ongoing with topline final results expected in the fourth quarter of  previously announced interim results after compl pdf jul   redhill biopharma reports  second quarter financial results redhill maintains a strong and debtfree balance sheet with  million in cash at the end of the second quarter allowing the company to continue to diligently execute its three ongoing phase iii gastrointestinal disease programs in the us as well as additional clinical programsrecent key milestones include first patients dosed in the phase  pdf jul   redhill biopharma receives additional us patent covering rhb ahead of confirmatory phase iii study for h pylori infection redhill has received a notice of allowance for an additional us patent covering rhb expected to be valid until  once grantedthe planned confirmatory phase iii study with rhb for the treatment of h pylori infection if successful is expected to support a us new drug application nda the first phase iii study with rhb successf pdf jul   redhill biopharma to host second quarter  financial results conference call on july   telaviv israel july   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases includi pdf jul   redhill biopharma announces research collaboration with nih for potential ebola treatment telaviv israel july   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases and cancer pdf jul   redhill biopharma and intelgenx announce definitive agreement for commercialization of rizaport™ for migraines with grupo juste in spain and additional potential territories redhill and its codevelopment partner intelgenx have signed a definitive agreement with grupo juste granting an exclusive license to commercialize their acute migraine drug rizaport™ in spain and a right of first refusal for additional territories grupo juste is a prominent private spanish company with over  years of experience in the r pdf jun   redhill biopharma announces publication demonstrating potential efficacy of rhb for crohns disease associated with map infection the peerreviewed article authored by scientists from the university of central florida concludes that the triple combination of the rhb active components provides excellent synergistic activity in the inhibition of mycobacterial growth potentially leading to a new and effective treatment for crohns disease associated with mycobacterium avi pdf jun   redhill biopharma announces positive final results with primary and secondary endpoints met in phase  study with yeliva™ in advanced solid tumors final results from the phase i study with yeliva™ abc in patients with advanced solid tumors confirmed that the study conducted at the medical university of south carolina musc successfully met its primary and secondary endpoints demonstrating that the drug is well tolerated and can be safely administered to cancer patients at do pdf jun   redhill biopharma announces first patients dosed in phase ii study with bekinda™ for ibsd the first patients have been dosed in the randomized doubleblind placebocontrolled phase ii study with bekinda™  mg for the treatment of diarrheapredominant irritable bowel syndrome ibsd in  subjects in  clinical sites in the us  ibs is one of the most common gastrointestinal disorders estimated to affect at least  million pdf jun   redhill biopharma to present at jmp securities life sciences conference telaviv israel june   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases and canc pdf may   redhill biopharma to present at the  bio international convention telaviv israel may   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases and cance pdf may   redhill biopharma to present at jefferies  healthcare conference telaviv israel may   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases and cance pdf may   redhill biopharma announces national cancer institute grant supporting yeliva™ phase ii hepatocellular carcinoma study the  million us national cancer institute nci grant awarded to the medical university of south carolina musc is intended to support a research program covering a variety of solid tumor cancers including a phase ii study with yeliva™ abc for the treatment of advanced hepatocellular carcinoma planned to be initiated in q pdf apr   redhill biopharma reports  first quarter financial results redhill maintains a strong and debtfree balance sheet with approximately  million in cash at the end of the first quarter allowing the company to continue to diligently execute its strategic and operational plans including its three ongoing phase iii gastrointestinal disease programs in the us             key milestones in the first quarter pdf apr   redhill biopharma to participate in the fbr  co healthcare series focused on infectious diseases telaviv israel april   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases includ pdf apr   redhill biopharma announces positive fda meeting on rhb path to approval and planned confirmatory phase iii study for h pylori infection the fda has confirmed subject to final minutes of the meeting the planned twoarm randomized doubleblind active comparator design of the confirmatory phase iii study with rhb for the treatment of h pylori infection expected to be initiated in the second half of   based on fda feedback and subject to successful completion the plann pdf apr   redhill biopharma to host first quarter  financial results conference call on april   telaviv israel april   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases includ pdf apr   redhill biopharma initiates phase ii study of bekindatm for irritable bowel syndrome the randomized doubleblind arm parallel group phase ii study of bekindatm  mg is expected to enroll  patients suffering from diarrheapredominant irritable bowel syndrome ibsd in  clinical sites in the us  the us potential market for ibsd treatments is estimated to exceed  billion by   a phase iii study with bekindatm pdf apr   redhill biopharma initiates phase ii study of bekinda™ for irritable bowel syndrome the randomized doubleblind arm parallel group phase ii study of bekinda™  mg is expected to enroll  patients suffering from diarrheapredominant irritable bowel syndrome ibsd in  clinical sites in the us the us potential market for ibsd treatments is estimated to exceed  billion by  a phase iii study with bekinda pdf mar   redhill biopharma announces interim results from phase iia proofofconcept study supporting therapeutic potential of rhb in multiple sclerosis the ongoing ceasems phase iia proofofconcept poc singlearm openlabel study was designed with a series of exploratory endpoints to evaluate the safety and potential efficacy of fixed oral dose rhb as addon therapy to interferon betaa in  patients treated for relapsingremitting multiple sclerosis rrmsinterim results after complet pdf mar   redhill biopharma and intelgenx announce rizaporttm commercialization term sheet with grupo juste for spain and additional potential territories redhill and its codevelopment partner intelgenx corp have entered into a binding term sheet with grupo juste granting an exclusive license to commercialize their acute migraine drug rizaporttm in spain and a right of first refusal for additional territories   grupo juste is a prominent private spanish company with over  years of experience pdf mar   redhill biopharma to present at bioeurope spring  conference telaviv israel march   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases in pdf mar   redhill biopharma announces peerreviewed publication demonstrating therapeutic potential of yeliva™ in cholangiocarcinoma cancer the article was authored by scientists from the mayo clinic cancer center the hollings cancer center at the medical university of south carolina and apogee biotechnology corporation  redhill announced in october  positive topline results from a phase i study with yeliva™ abc in patients with advanced solid tumors the majority o pdf mar   redhill biopharma to present at the th annual roth conference telaviv israel march   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases in pdf mar   redhill biopharma reports successful final results of phase iii study with rhb for h pylori infection the rhb first phase iii clinical study report demonstrates the efficacy and safety of rhb in eradication of h pylori infection supports the potential superior efficacy of rhb over current standardofcare therapies and confirms the positive topline results previously announced  a meeting with the fda is scheduled for april  to di pdf mar   redhill biopharma provides  rd update redhills advanced pipeline includes three phase iii programs several phase ii programs and additional earlystage programs redhill maintains a strong and debtfree balance sheet allowing the company to continue to execute its development plans key potential highlights for  includeredhill has completed enrollment of over half of the pat pdf feb   redhill biopharma announces availability of its annual report on form f through its website telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company a biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases inc pdf feb   redhill biopharma reports  fourth quarter and fullyear financial results key highlights include redhill maintains a strong and debtfree balance sheet with approximately  million in cash and cash equivalents at the end of  allowing the company to continue to execute its development plans key milestones in  include positive topline results from the first phase iii study with rhb for h pylori infec pdf feb   redhill biopharma announces notice of allowance for us patent covering rizaport™ for migraines the new us patent is expected to be valid until  once granted redhill and its codevelopment partner intelgenx corp recently announced the national approval of rizaport™ in germany under the european decentralized procedure dcp redhill and intelgenx continue to work together to secure commercialization partners for rizaport™ pdf feb   redhill biopharma to host  fourth quarter and yearend financial results conference call on february   telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal dise pdf feb   redhill biopharma appoints dr june s almenoff and ms theresa m stevens to advisory board dr almenoff previously served as president principal executive officer and chief medical officer of furiex pharmaceuticals now actavis plcms stevens previously served as chief corporate development officer and senior vice president at aptalis pharma now actavis plc telaviv israel feb   globe newswire  redhill biopharma ltd pdf feb   redhill biopharma announces successful pk study with bekinda™  mg and submission to fda of ibsd phase ii study protocol redhill recently concluded a successful firstinman pharmacokinetic pk study with bekinda™  mg rhb proprietary formulation to support the planned phase ii study for the treatment of diarrheapredominant irritable bowel syndrome ibsdredhill submitted to the fda the protocol for the phase ii ibsd study under the existing bekinda pdf feb   redhill biopharma receives notice of allowance of fifth us patent covering rhb phase iii crohns disease program once granted the new us patent covering methods of use for rhb is expected to be valid through rhb is undergoing a first phase iii study for the treatment of crohns disease in the us and additional countries with interim analysis expected during the second half of a phase iia proofofconcept study evaluating rhb in patie pdf feb   redhill biopharma issues letter to shareholders telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal dise pdf feb   redhill biopharma announces collaboration with germanys fraunhofer institute for oncology drug rp telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal dise pdf feb   redhill biopharma to present at the th annual bio ceo  investor conference telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal dise pdf jan   redhill biopharma to present at biotech showcase  telaviv israel jan   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal dise pdf dec   redhill biopharma announces appointment of micha ben chorin as chief financial officer telaviv israel dec   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal dise pdf dec   redhill biopharma announces appointment of rick d scruggs to board of directors telaviv israel dec   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal dise pdf nov   redhill biopharma announces completion of dosing in phase iia study of rhb for multiple sclerosis topline interim results from the phase iia proofofconcept clinical study of rhb in patients treated for relapsingremitting multiple sclerosis the ceasems study are expected by early q the phase iia study is intended to evaluate the safety and efficacy of rhb as an addon therapy to interferon betaa following  week pdf nov   redhill biopharma announces passing of board member alicia rotbard telaviv israel nov   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseas pdf nov   redhill biopharma to present at the jefferies autumn  global healthcare conference telaviv israel nov   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases including cancer today announced th pdf nov   redhill biopharma reports results for the third quarter of  key highlights include a strong cash position of approximately  million at the end of the third quarter of  following the companys july  public offering in the us with gross proceeds of  million recent key milestones include the first european marketing approval of rizaport™ announced today positi pdf nov   redhill biopharma and intelgenx announce first european marketing approval of rizaporttm rhb for migraines the german federal institute for drugs and medical devices bfarm has granted national marketing approval for rizaporttm rhb for the treatment of acute migraines under the european decentralized procedure dcp redhill and intelgenx continue their close cooperation in order to obtain approvals in additional european countries and in the u pdf oct   redhill biopharma to host third quarter  financial results conference call on november   telaviv israel oct   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases including cancer today announced tha pdf oct   redhill biopharma to present at the bioeurope  conference telaviv israel oct   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases including cancer today announced tha pdf oct   redhill biopharma announces positive topline results from yelivatm abc phase i study in advanced solid tumors the phase i study with yeliva™ abc successfully met its primary and secondary endpoints demonstrating that the drug is well tolerated and can be safely administered to cancer patients at doses that provide circulating drug levels that are predicted to have therapeutic activity twentyone patients with advanced solid tumors pdf oct   redhill biopharma to present at gelbartkahana biomed conference on october   telaviv israel oct   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases including cancer today announced tha pdf oct   redhill biopharma announces planned management changes telaviv israel oct   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases including cancer today announced tha pdf oct   redhill biopharma announces national cancer institute grant awarded to apogee biotechnology corp for yelivatm abc prostate cancer research the  us national cancer institute nci grant was awarded to apogee biotechnology corporation from which redhill acquired the exclusive worldwide rights to yeliva™ abc in march  a phase iii study with yeliva™ abc was recently initiated in the us in patients with refractoryrelapsed di pdf oct   redhill biopharma to present at the bionetwork west partnering summit telaviv israel oct   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases including cancer today announced tha pdf oct   redhill biopharma provides update on bekindatm ongoing phase iii study for gastroenteritis and announces planned phase ii study for ibsd based on recent us fda feedback and prior feedback from the uk mhra redhill believes that the ongoing phase iii study with bekinda™ for gastroenteritis the guard study may be sufficient as a single study to support the filing of a marketing application in the us and europe subject to achieving highly significant positive results  pdf sep   redhill biopharma and intelgenx announce rizaporttm rhb marketing authorization application is approvable under the european decentralized procedure the german federal institute for drugs and medical devices bfarm has confirmed the positive outcome of the european decentralized procedure and informed redhill and intelgenx that the european marketing authorization application maa for rizaport™ rhb is approvable redhill and intelgenx plan to submit the final required do pdf sep   redhill biopharma announces  million national cancer institute grant for yelivatm abc phase ii study for multiple myeloma the national cancer institute nci  million grant is intended to support the phase ii study with yeliva™ abc for refractory or relapsed multiple myeloma planned to be initiated by redhill at duke university medical center by the end of  yeliva™ abc is a proprietary firstinclass orallyadministered s pdf sep   redhill biopharma announces standardofcare eradication data from the rhb phase iii study further supporting the studys positive results patients enrolled in the placebo arm of the eradicate hp phase iii study received openlabel standardofcare soc therapy for persistent helicobacter pylori h pylori infection results from this group demonstrated a  h pylori eradication rate compared to the previously announced  eradication rate demonstrated in the rhb arm of th pdf sep   redhill biopharma to present at the rodman  renshaw th annual global investment conference telaviv israel sept   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal gi diseases including gastrointestinal cance pdf sep   redhill biopharma announces last patient visit in the phase i study with yelivatm abc for advanced solid tumors the openlabel doseescalation pharmacokinetic pk and pharmacodynamic pd phase i study with yeliva™ abc in patients with advanced solid tumors was supported by grants from the national cancer institute nci and the fdas office of orphan products development oopd  analysis of the study is ongoing with topli pdf aug   redhill biopharma receives notice of allowance for new israeli patent covering rhb for the treatment of crohns disease once granted the new israeli patent is expected to be valid through at least  further extending redhills global patent portfolio covering rhb rhb is undergoing a first phase iii study for the treatment of crohns disease in the us and additional countries the map us study a second phase iii study with rhb  pdf aug   redhill biopharma announces peerreviewed publication demonstrating therapeutic potential of abc yelivatm in prostate cancer the publication in the peerreviewed journal molecular cancer research details promising preclinical results suggesting abc significantly inhibits prostate cancer tumor growth redhill filed a trademark application with the us patent and trademark office for the new brand name yeliva™ for abc yeli pdf aug   redhill biopharma to present rhb phase iii crohns program at the international research symposium on crohns disease telaviv israel aug   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers t pdf jul   redhill biopharma reports results for the second quarter of  key highlights include strong cash position of approximately  million at the end of the second quarter of  and approximately  million as of july   following the companys july  public offering in the us gross proceeds of  million from the companys july  public offering in the us pdf jul   redhill biopharma provides update on rhb program partnered with salix pharmaceuticals salix pharmaceuticals recently acquired by valeant pharmaceuticals confirmed to redhill that it continues the development of redhills rhb encapsulated bowel preparation salix further clarified to redhill that the purgative tablet formulation referenced in valeants second quarter  earnings call presentation as a failed toxicolo pdf jul   redhill biopharma to host second quarter  financial results conference call on july   telaviv israel july   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers t pdf jul   redhill biopharma announces closing of public offering of its american depository shares telaviv israel july   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers i pdf jul   redhill biopharma prices public offering of its american depository shares telaviv israel july   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers t pdf jul   redhill biopharma announces size of proposed public offering of its american depository shares filed pursuant to rule  of the securities act of   issuer free writing prospectus dated july   registration no   telaviv israel july   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late cl pdf jul   redhill biopharma extends option agreement for phase iistage pancreatic cancer drug rp redhill has extended the term of the exclusive option agreement for the oncology drug candidate rp for an additional year rp is a proprietary firstinclass orallyadministered heat shock protein  hsp inhibitor intended to prevent the induction of resistance to chemotherapy chemoresistance to potentially enhance pat pdf jul   redhill biopharma announces proposed public offering of its american depository shares telaviv israel july   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers t pdf jul   redhill biopharma receives authorization in australia and new zealand for ongoing phase iii crohns disease study with rhb the phase iii study with rhb for crohns disease is currently ongoing in the us and additional countries with up to  clinical sites planned globally the map us study a clinical trial application for a second phase iii study with rhb for crohns disease in europe the map eu study was recently accepted by the uk mhra  pdf jul   redhill biopharma receives notice of allowance for two additional us patents covering rhb ongoing phase iii crohns disease program once granted the two new us patents covering rhb are expected to be valid through  rhb is undergoing a first phase iii study for the treatment of crohns disease in the us and additional countries a second phase iii study with rhb for crohns disease is planned in europe following clinical trial application pdf jun   redhill biopharma initiates phase iii study of abc for refractory lymphoma the phase iii study led by dr chris parsons md associate professor at louisiana state university health sciences center is intended to evaluate the safety and tolerability of abc in patients with refractoryrelapsed diffuse large bcell lymphoma dlbcl primarily patients with hivrelated dlbcl abc is a proprietary fir pdf jun   redhill biopharma announces acceptance of phase iii trial application in europe with rhb for crohns disease telaviv israel june   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today annou pdf jun   redhill biopharma to present at the  bio international convention telaviv israel june   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers t pdf jun   redhill biopharma to host conference call today to review positive phase iii topline results with rhb for h pylori infection telaviv israel june   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today annou pdf jun   redhill biopharma successfully meets primary endpoint in phase iii study of rhb for h pylori infection topline results from the rhb phase iii study demonstrated  efficacy in eradicating h pylori infection with rhb the phase iii study successfully met its primary endpoint of superiority over historical standard of care efficacy levels of  with high statistical significance p pdf jun   redhill biopharma announces completion of patient enrollment in the phase iia study of rhb for multiple sclerosis the last patient has been enrolled in the phase iia proofofconcept clinical study evaluating rhb as an addon therapy to interferon betaa in patients treated for relapsingremitting multiple sclerosis the ceasems study interim results from the phase iia ceasems study are expected in q  q rhb is also b pdf jun   redhill biopharma completes treatment of last patient with rhb in phase iii study last patient has completed treatment course with rhb for primary endpoint evaluation the phase iii topline results with rhb for the treatment of h pylori bacterial infection are expected during the third week of june  subject to completion of review requirements rhb targets a significantly broader indication  pdf jun   redhill biopharma provides update on development pipeline and expected timing for rhb phase iii topline results key highlights and upcoming anticipated milestones include phase iii topline results with rhb for the treatment of h pylori bacterial infection are expected during the third week of june  subject to completion of review requirements phase iii topline results with bekinda™ for gastroenteritis and gastritis pdf may   redhill biopharma to present at the jefferies  global healthcare conference telaviv israel may   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered small molecule drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced tha pdf may   redhill biopharmas investor webcast forum provides update on the rhb phase iii program and potential h pylori eradication market redhills investor webcast forum held on may   focused on the development program for rhb currently undergoing a first phase iii study eradicate hp study for the treatment of h pylori bacterial infection with topline results expected in midend june  key opinion leader prof david graham md discussed the role of pdf may   redhill biopharma to present at the biotrinity  partnering conference telaviv israel may   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced that adi frish redhills senior pdf may   redhill biopharma to host investor webcast forum following completion of rhb dosing in phase iii study redhill will host an interactive investor forum on h pylori bacterial infection and rhb on thursday may   at  am eastern time participants are invited to join the forum through the companys website or by telephone rhb dosing has been completed in the blinded stage of the eradicate hp study  a randomized pla pdf may   redhill biopharma to present at the oppenheimer th annual israeli conference telaviv israel may   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced tha pdf apr   redhill biopharma reports results for the first quarter of  key highlights include strong cash position of approximately  million at the end of the first quarter of  following the closing of the companys first public offering in the us including participation by leading institutional healthcare investors key milestones achieved in the first quarter of  included the  pdf apr   redhill biopharma to present at the bionetwork east  partnering conference telaviv israel april   globe newswire  redhill biopharma ltd nasdaqrdhl tase rdhl redhill an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced that dror benas pdf apr   redhill biopharma announces completion of patient enrollment in a phase iii study of rhb for h pylori infection the last patient has been enrolled in the eradicate hp study  a randomized placebocontrolled first phase iii study evaluating rhb as a firstline therapy for h pylori bacterial infection a major cause of chronic gastritis peptic ulcer disease gastric cancer and malt lymphoma topline results from the phase iii study are expect pdf apr   redhill biopharma to host first quarter  financial results conference call on april   telaviv israel april   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced  pdf apr   redhill biopharma receives notice of allowance for additional us patent for rhb h pylori bacterial infection treatment the us patent and trademark office uspto has issued a notice of allowance for a new formulation patent application covering rhb h pylori bacterial infection treatment to expire no earlier than  topline results from the ongoing phase iii study with rhb are expected in june  rhb targets a significantly pdf mar   redhill biopharma acquires phase ii firstinclass oral small molecule sk inhibitor from apogee biotech abc is a proprietary firstinclass new chemical entity nce sphingosine kinase sk inhibitor administered orally which has successfully completed numerous preclinical studies and a phase i study in cancer patients with advanced solid tumors abc targets multiple inflammatory gastrointestinal and oncology indications pdf mar   redhill biopharma to present at the rd annual autoimmune  inflammation leaders forum  telaviv israel march   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced that ira kalfus  pdf mar   redhill biopharma to present at virtualinvestorconferencescom online event on march   telaviv israel march   prnewswire  redhill biopharma ltd nasdaqtase rdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced that guy go pdf mar   redhill biopharma to present at bioeurope spring  international partnering conference telaviv israel march   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced t pdf mar   redhill biopharma to present at the th annual roth conference telaviv israel march   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced t pdf mar   positive bioavailability studies of redhills bekindatm to be presented at the  american society for clinical pharmacology and therapeutics ascpt meeting the results from two positive bioavailability studies previously reported by the company demonstrate the safety and tolerability of bekinda™ and support the european marketing application submitted for bekinda™ and the planned submission of a us new drug application nda for oncology support a european marketing authoriza pdf feb   redhill biopharma reports  fourth quarter and yearend financial results key highlights include strong cash position of over  million following completion of a  million us public offering in february  with three ongoing phase iii clinical studies for gastrointestinal diseases rd expenses increased to  million in  compared to  million in  anticipated  pdf feb   redhill biopharma to host  fourth quarter and yearend financial results conference call on february   telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced t pdf feb   redhill biopharma announces full exercise of underwriters overallotment option telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced t pdf feb   redhill biopharma announces closing of public offering of its american depository shares telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers is today announci pdf feb   redhill biopharma to present at the life sciences israeltm  rd annual international partnering conference telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced that dror benashe pdf feb   redhill biopharma prices public offering of its american depository shares telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced p pdf feb   redhill biopharma announces proposed public offering of its american depository shares telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill or the company an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced th pdf jan   redhill biopharma provides update on progress with rhb ongoing phase iii program for crohns disease following fda meeting redhill and quest diagnostics concluded a presubmission meeting with us fda regarding redhills companion diagnostic test for the detection of map bacterium an extension of redhills ongoing rhb phase iii crohns disease development program increasing evidence supports the hypothesis that crohns disease is caused by map inf pdf jan   redhill biopharma to present at the th annual bio ceo  investor conference telaviv israel jan   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced that dror benashe pdf jan   redhill biopharma to present at biotech showcasetm  conference in san francisco telaviv israel jan   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill an israeli biopharmaceutical company primarily focused on late clinicalstage proprietary orallyadministered drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced that adi frish red pdf jan   redhill biopharma business outlook and anticipated key milestones for  upcoming milestones include topline data from ongoing first phase iii study with rhb for h pylori infection expected q topline data from ongoing phase iii study with bekinda™ rhb for gastroenteritis and gastritis expected qq telaviv israel jan   globe newswire  redh pdf dec   redhill biopharma announces acceptance for review of bekindatm european marketing application for oncology support the uk mhra has validated the european marketing application for the indications of chemotherapy and radiotherapyinduced nausea and vomiting mhras feedback is expected during h   bekinda™ rhb is a proprietary oncedaily oral pill formulation of the antiemetic drug ondansetron targeting a worldwide potential market wi pdf dec   redhill biopharma acquires technology from university of minnesota as part of ongoing rhb phase iii crohns program the acquired diagnostic technology is intended for the detection of mycobacterium avium subspecies paratuberculosis map bacterium increasing evidence supports the hypothesis that crohns disease is caused by map infection in susceptible patients redhill is developing a map diagnostic test in collaboration with quest diagnostics and pl pdf dec   redhill biopharma announces first patients enrolled in the phase iii study of rhb bekindatm for gastroenteritis and gastritis the randomized doubleblind placebocontrolled phase iii study with rhb for acute gastroenteritis and gastritis the guard study is underway in the us with a planned enrollment of  patients topline results from the phase iii guard study are expected during h redhill recently submitted a european m pdf dec   redhill biopharma submits bekindatm rhb european marketing authorization application for oncology support rhb newly branded as bekinda™ is a proprietary oncedaily oral pill formulation of the antiemetic drug ondansetron the european marketing authorization application maa seeks approval of bekinda™ for cancer patients suffering from chemotherapy and radiotherapyinduced nausea and vomiting bekinda™ is also pdf dec   redhill biopharma to sponsor and exhibit its ongoing phase iii crohns program at the israeli ibd society meeting telaviv israel dec   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill an israeli biopharmaceutical company focused on late clinicalstage drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced that it will provide silver sponsorship for the israeli ibd in pdf dec   redhill biopharma and intelgenx announce acceptance for review of european marketing application for rizaporttm for migraines the german federal institute for drugs and medical devices bfarm has validated the european marketing authorization application submitted for rizaport™ rhb and initiated its formal review of the application on november   redhill and intelgenx continue to work with the fda to resolve the remaining chemistry manufactu pdf nov   fda grants qidp fasttrack designation to redhill biopharmas phase iii h pylori drug rhb under the fdas generating antibiotic incentives now gain act the qualified infectious disease product qidp designation allows for additional five years of market exclusivity in addition to existing exclusivity fasttrack status an expedited development pathway and priority review status shortened review time for marketing applications  pdf nov   redhill biopharma reports results for the third quarter of  a strong cash position of approximately  million at the end of the third quarter of  enabling the company to continue to execute its rd programs including the three ongoing phase iii studies in gastrointestinal indications rhb for crohns disease rhb for h pylori infection and rhb for acute gastroenteritis and gastritis  pdf oct   redhill biopharma to host third quarter  financial results conference call on november   telaviv israel oct   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill an israeli biopharmaceutical company focused on late clinicalstage drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced that it will report financial results for the third quarter of pdf oct   redhill biopharma to present at the th annual bioeurope international partnering conference telaviv israel oct   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an israeli biopharmaceutical company focused on late clinicalstage drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced that adi frish redhills senior vp business  pdf oct   intelgenx and redhill biopharma submit european marketing authorization application for migraine drug rizaportr saint laurent quebec oct   globe newswire  intelgenx corp tsxvigx otcqxigxt intelgenx a canadian drug delivery company focused on oral drug delivery today announced together with redhill biopharma ltd nasdaqrdhl taserdhl redhill an israeli biopharmaceutical company focused on late clinicalstage drugs for inf pdf oct   redhill biopharma and intelgenx submit european marketing authorization application for migraine drug rizaportr formerly rhb telaviv israel oct   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill an israeli biopharmaceutical company focused on late clinicalstage drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced together with intelgenx corp tsxvigx otcqxigxt intel pdf sep   redhill biopharma to present at the th annual biotech in europe forum for global partnering  investment telaviv israel sept   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an israeli biopharmaceutical company focused on late clinicalstage drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced that adi frish redhills senior vp business pdf sep   redhill biopharma to present at the th annual biopharm america international partnering conference telaviv israel sept   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an israeli biopharmaceutical company focused on late clinicalstage drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced that adi frish redhills senior vp business pdf sep   redhill biopharma to present at the rodman  renshaw th annual global investment conference telaviv israel sept   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an israeli biopharmaceutical company focused on late clinicalstage drugs for inflammatory and gastrointestinal diseases including gastrointestinal cancers today announced that dror benasher redhills chief executiv pdf sep   redhill biopharma initiates phase iii study of rhb for gastroenteritis the randomized doubleblind placebocontrolled parallel group phase iii study with rhb the guard study will enroll  acute gastroenteritis patients in the us acute gastroenteritis is an inflammation of the gastrointestinal tract causing nausea and vomiting with a potential worldwide market estimated to exceed  million  pdf aug   redhill biopharma provides update on expansion of ongoing rhb phase iii study targeting broadened h pylori indication authorized by fda in order to enhance statistical powering and expedite recruitment redhill has increased the number of subjects and clinical sites respectively in the ongoing rhb phase iii eradicate hp study with topline data currently expected in the first half of  fda has permitted redhill to pursue with rhb a significantly broader ind pdf aug   redhill biopharma acquires option for phase ii pancreatic cancer drug rp potentially expanding its gastrointestinalfocused pipeline redhill has secured an option to acquire rp from dresdenbased resprotect gmbh a spinoff from the fraunhofersociety rp has completed several phase i and phase ii clinical studies rp has been granted orphan drug designation for the adjunct treatm pdf jul   redhill biopharma reports results for the second quarter of  highlights include a strong cash position of approximately  million at the end of the second quarter of  following the acquisition of rights to mesupron® a phase ii drug targeting gastrointestinal cancers topline data from the phase iii study of rhb for h pylori infection expected in q  pdf jul   redhill biopharma to host second quarter  financial results conference call on july   telaviv israel july   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an israeli biopharmaceutical company focused on late clinicalstage drugs for inflammatory and gastrointestinal diseases including cancer today announced that it will report financial results for the second quarter of pdf jun   redhill biopharma acquires phase ii oncology drug mesupronr from wilex ag redhill expands its late clinicalstage gastrointestinalfocused pipeline with mesupron® an oncology drug targeting gastrointestinal and other solid tumor cancers licensed from wilex ag mesupron® completed several phase i and phase ii clinical studies including a phase ii proof of concept study in locally advanced nonmetastat pdf jun   redhill biopharma announces positive preliminary preclinical data with rhb for the treatment of type  diabetes the company primarily focused on gastrointestinal and inflammatoryrelated diseases and conditions including cancer is currently assessing the possibility of a phase ii proof of concept study for type  diabetes subject to final results and an independent report expected in the coming weeks a phase iii study with rhb for c pdf jun   redhill biopharma to present at the  bio international convention telaviv israel june   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary drugs for the treatment of inflammatory and gastrointestinal diseases and related con pdf jun   redhill biopharma to present at the wells fargo securities th annual healthcare conference telaviv israel june   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary drugs for the treatment of inflammatory and gastrointestinal diseases and related con pdf jun   redhill biopharma announces new rhb patent in japan and provides update on phase iii crohns program the japan patent office jpo has issued a decision to grant a patent covering rhb with a  expiry date redhill has initiated a longterm population pharmacokinetic study with rhb for crohns disease designed to satisfy regulatory requirements for future potential marketing applications the planned number of clinical pdf jun   redhill biopharma to present at jefferies  global healthcare conference telaviv israel june   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary drugs for the treatment of inflammatory and gastrointestinal diseases and related cond pdf may   redhill biopharma announces fda clearance for phase iii study with rhb planned to commence in q fdas clearance of redhills investigational new drug ind amendment allows the initiation of a phase iii clinical study for a new undisclosed indication with rhb a proprietary oncedaily extended release oral pill formulation of the antiemetic drug ondansetron in parallel to pursuing the new undisclosed indication redhi pdf may   intelgenx and redhill biopharma report positive bioavailability study results in support of planned european marketing application in q for antimigraine versafilmtm product saint laurent quebec may   globe newswire  intelgenx corp tsxvigx otcqxigxt intelgenx a canadian drug delivery company focused on oral drug delivery today reported together with redhill biopharma ltd nasdaqrdhl taserdhl redhill an emerging israeli biopharmaceutical company focused primarily on the development pdf may   redhill biopharma and intelgenx report positive rhb bioavailability study results in support of planned european marketing application in q telaviv israel may   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary drugs today reported together with intelgenx corp tsxvigx otcqxigxt intelgenx a canadian pdf may   redhill biopharma to present at the chinabio partnering forum  telaviv israel may   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary drugs for the treatment of inflammatory and gastrointestinal diseases including cancer and related condi pdf apr   redhill biopharma reports results for the first quarter of  key financial highlights include a first profitable quarter with net income of  million primarily attributed to the  million upfront payment received from salix pharmaceuticals as part of the licensing transaction for the rights to redhills rhb encapsulated bowel preparation and related rights redhill r pdf apr   redhill biopharma reports successful rhb bioavailability clinical trial and planned submission of european marketing application in q redhill received positive results from a comparative bioavailability clinical trial which included  healthy volunteers in light of the positive results and subject to regulatory requirements the company plans to submit during the third quarter of this year a european marketing application for rhb for the prevention of ch pdf apr   redhill biopharma to host first quarter  financial results conference call on may   telaviv israel april   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary drugs for the treatment of inflammatory and gastrointestinal diseases including can pdf apr   redhill biopharma and intelgenx announce commencement of a bioavailability study with rhb migraine to support european marketing application planned for q telaviv israel april   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary drugs together with intelgenx corp tsxvigx otcqxigxt intelgenx a canadian drug delivery  pdf apr   intelgenx and redhill biopharma provide an update on fdas ongoing review of the nda for migraine versafilmtm product saint laurent quebec april   globe newswire  intelgenx corp tsxvigx otcqx igxt intelgenx a canadian drug delivery company focusing on oral drug delivery together with redhill biopharma ltd nasdaqrdhl taserdhl redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisi pdf apr   redhill biopharma and intelgenx provide an update on fdas ongoing review of the nda for rhb oral migraine film telaviv israel april   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary drugs together with intelgenx corp tsxvigx otcqxigxt intelgenx a canadian drug delivery pdf apr   redhill biopharma announces positive european scientific advice meeting regarding rhb and plans to submit a european marketing application the company concluded a positive scientific advice meeting with the uk mhra regarding rhb and plans to submit during the second half of the year a european marketing application for the prevention of chemotherapy and radiotherapyinduced nausea and vomiting in cancer patients rhb is a proprietary oncedaily oral pill f pdf mar   redhill biopharma to present at the th annual roth conference telaviv israel march   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary drugs for the treatment of inflammatory and gastrointestinal diseases and related co pdf mar   redhill biopharma provides update on rhb development and intellectual property rhb is a proprietary oncedaily oral antiemetic redhill has secured from temple university direct rights to the original rhb patents and has terminated its agreement with scolr pharma inc following a prenda meeting on rhb s development for oncology support redhill has provided the fda with additional information pdf mar   redhill biopharma and intelgenx submit response to fda crl for rhb migraine oralfilm telaviv israel march   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage drugs today announced together with intelgenx corp tsxvigx otcqxigxt intelgenx a canadian drug deli pdf feb   redhill biopharma and salix pharmaceuticals announce worldwide exclusive license agreement for redhills rhb encapsulated bowel preparation telaviv israel feb   globe newswire  salix pharmaceuticals ltd nasdaqslxp and redhill biopharma ltd nasdaqrdhl taserdhl today announced that they have entered into an exclusive agreement by which salix has licensed the worldwide exclusive rights to redhills rhb encapsulated formulation for bowel preparation and rights pdf feb   redhill biopharma reports  fourth quarter and yearend financial results  key highlights include strong cash position of over  million as of february  following two private placements in early  and the exercise of warrants including by directors and management net rd expenses of  million during  compared to  million in  substantial progress in clini pdf feb   intelgenx and redhill biopharma receive complete response letter from fda for versafilmtm oral film product for acute migraines fdas letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies intelgenx and redhill plan to address remaining issues primarily related to third party manufacturing packaging and labeling within weeks based on available data in light of the increased regulatory clarity pdf feb   redhill biopharma and intelgenx receive complete response letter from fda for rhb oral film for acute migraines fdas letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies redhill and intelgenx plan to address remaining issues primarily related to third party manufacturing packaging and labeling within weeks based on available data in light of the increased regulatory clarit pdf jan   redhill biopharma closes previously announced  million private placement telaviv israel jan   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary formulations and combinations of existing drugs announced that it has closed on ja pdf jan   redhill biopharma announces definitive agreement for  million private placement telaviv israel jan   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary formulations and combinations of existing drugs today announced that it has entered pdf jan   redhill biopharma provides update on pk program in support of ongoing rhb phase iii crohns study preliminary positive safety results received from a phase i study with rhb in  healthy adult subjects additional pk studies with rhb are planned including longterm population pk and drugdrug interaction studies to support potential future marketing applications telaviv israel jan   globe newswire  r pdf dec   redhill biopharma announces definitive agreement for  million private placement from broadfin capital llc telaviv israel dec   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary formulations and combinations of existing drugs today announced that it has entered pdf dec   redhill biopharma announces definitive agreement for  million private placement from orbimed israel partners limited partnership telaviv israel dec   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary formulations and combinations of existing drugs today announced that it has entered pdf dec   redhill biopharma reports positive pk results in support of ongoing rhb phase iii h pylori study the positive results from the pharmacokinetic study support the continuation of the eradicate hp study  a phase iii clinical study currently underway in the us evaluating rhb as a firstline therapy for h pylori bacterial infection the objectives of the pk study were to evaluate rhbs pharmacokinetics and bioavailability pro pdf dec   redhill biopharma announces first patients dosed in phase iii study of rhb for h pylori infection the first patients have been dosed in the eradicate hp study  a randomized doubleblind placebocontrolled phase iii study evaluating rhb as a firstline therapy for h pylori bacterial infection seven of the eight clinical sites in the us are actively enrolling patients with the last site expected to commence enrollment shortl pdf nov   redhill biopharma announces first patient dosed in phase iii study of rhb for crohns disease first patient has been recruited and dosed in the map us study  a randomized doubleblind placebocontrolled phase iii clinical study to evaluate the safety and efficacy of rhb for treatment of crohns disease the phase iii study is expected to enroll  subjects in over  clinical sites in the us canada and israel subjects w pdf nov   redhill biopharma announces positive scientific advice meeting and european marketing application strategy for rhb migraine the company and its codevelopment partner intelgenx corp held a scientific advice meeting with the german pharmaceuticals regulation authority bfarm and plan to submit a marketing authorization application maa to market rhb in europe during the first half of  rhb is a proprietary oral thin film formulation of riz pdf nov   redhill biopharma reports results for the third quarter of  key highlights include commencement of the map us study — a phase iii clinical study in north america and israel with rhb for the treatment of crohns disease commencement of the eradicate hp study — a phase iii clinical study in the us with rhb for the treatment of h pylori bacterial infection  pdf oct   redhill biopharma to present at the th annual bioeurope international partnering conference telaviv israel oct   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary formulations and combinations of existing drugs today announced that adi frish red pdf oct   redhill biopharma initiates phase iii study of rhb for h pylori infection redhill has initiated the patient screening process in the eradicate hp study  a randomized doubleblind placebocontrolled phase iii study to evaluate the safety and efficacy of rhb as a firstline therapy for h pylori bacterial infection subjects will be treated with rhb for a period of  days in up to  clinical sit pdf oct   redhill biopharma to present at the  annual bionetwork conference telaviv israel oct   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary formulations and combinations of existing drugs today announced that dror benasher pdf oct   redhill biopharma announces fda acceptance of ind application for rhb h pylori phase iii study  to commence shortly the phase iii study is expected to commence in the us by the end of this month rhb is a new and proprietary combination therapy in an oral capsule for the treatment of h pylori bacterial infection redhill recently commenced another phase iii study in the us with rhb for the treatment of crohns disease  pdf oct   redhill biopharmas rhb combination achieves  remission in independent pediatric crohns study the retrospective study presented at the  american college of gastroenterology acg annual scientific meeting demonstrated strong results with a high remission rate of  redhills rhb is a new and improved proprietary singlepill formulation of the combination of active ingredients used in the retrospective pediatric study  pdf oct   redhill biopharma reports positive pk clinical studies towards planned nda with rhb antiemetic following the positive results from two supportive pharmacokinetic pk studies the company plans to file a new drug application nda in the first quarter of  and is seeking a prenda meeting with the fda rhb is a proprietary extended release oncedaily oral formulation of ondansetron a leading drug for the prevention of naus pdf oct   redhill biopharma initiates phase iii study of rhb for crohns disease redhill has initiated the patient screening process in a randomized doubleblind placebocontrolled phase iii clinical study to evaluate the safety and efficacy of rhb for treatment of crohns disease the map us study the phase iii study is expected to enroll  subjects in approximately  clinical sites in the us canada and  pdf sep   redhill biopharma to present at the annual biopharm america international partnering conference telaviv israel sept   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary formulations and combinations of existing drugs today announced that dror benashe pdf sep   redhill biopharma announces positive preclinical results for lupus with rhb the company is assessing the possibility of a phase iia proof of concept study in systemic lupus erythematosus as a next step redhill expects to commence a phase iii study with rhb for crohns disease in the us during the third quarter of  the map us study and plans a second phase iii study for crohns in europe the map euro pdf sep   redhill biopharma to present at the stifel nicolaus annual healthcare conference telaviv israel sept   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage proprietary formulations and combinations of existing drugs today announced that dror benasher pdf aug   redhill biopharma announces positive european regulatory meetings regarding its european phase iii plan for rhb crohns the company recently held successful scientific advice meetings with the uk and swedish pharmaceutical regulatory agencies to discuss its european phase iii strategy with rhb for crohns disease the european trial will be the second phase iii study with rhb and is expected to recruit an estimated  pdf jul   redhill biopharma announces positive preclinical rheumatoid arthritis results with rhb and plans for a phase iia study the planned phase iia proof of concept clinical study will assess the efficacy and safety of rhb in patients suffering from rheumatoid arthritis ra ra is one of the most common inflammatory diseases with  worldwide sales of therapies exceeding  billion a phase iii clinical study with rhb for croh pdf jul   redhill biopharma reports results for the second quarter of  redhill continues advanced preparations for the phase iii study with rhb crohns and phase iiiii study with rhb h pylori key highlights include fda acceptance of rhb migraine nda for substantive review with a pdufa goal date of february   commencement of supplementary pk program with rhb pdf jul   redhill biopharma provides update on planned nda filing for rhb once daily antiemetic in q  and commences pk program following a type b meeting with the fda in february  the company commenced the first of two supplementary pharmacokinetic studies with rhb with a second comparative bioavailability study planned to commence next month the company expects to receive results from both studies by october  and plans to file a new drug applicati pdf jul   redhill biopharma to present at the jmp securities annual healthcare conference in new york telaviv israel july   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage patentprotected new formulations and combinations of existing drugs today announced that dror  pdf jun   redhill biopharma announces fda acceptance for review of rhb nda for acute migraine and pdufa goal date of february   the rhb new drug application nda for marketing approval in the us is subject to a standard month review period and will have a prescription drug user fee act pdufa action date targeted date for completion of fda review of february   the company recently received from fda a pdufa fee waiver and a subsequent refund of  pdf jun   redhill biopharma commences patient screening in a phase iia clinical trial with rhb for multiple sclerosis the open label phase iia study is designed to assess the efficacy and safety of rhb in multiple sclerosis ms patients the study follows successful completion of  preclinical studies a first phase iii clinical trial with rhb for crohns disease the map us study is planned to commence by the third quarter of  rec pdf may   redhill biopharma announces positive fda meeting regarding the regulatory path towards nda submission of rhb for the treatment of congestive heart failure and hypertension following the prior successful completion of four pharmacokinetic pk clinical studies the company held a type b meeting regarding rhb with the us food and drug administration fda based on the fdas positive feedback the company plans to conduct additional chemistry manufacturing and controls cmc and pk work prior to submi pdf may   redhill biopharma to present at the jefferies  global healthcare conference in new york telaviv israel may   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage patentprotected new formulations and combinations of existing drugs today announced that guy g pdf may   redhill biopharma reports financial results for the first quarter of  the company maintains a strong balance sheet following submission to the fda of its first new drug application nda for rhb migraine redhill plans to submit a second nda for rhb oncology support anti emetic by the first or second quarter of  and continues to advance the planned phase iii and phase iiiii studies with rhb pdf mar   redhill biopharma submits new drug application to us fda for rhb antimigraine oral thin film telaviv israel march   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage patentprotected new formulations and combinations of existing drugs today announced that the pdf mar   redhill biopharma receives positive feedback from a scientific advice meeting in europe regarding rhb hypertension marketing application plan the company held a scientific advice meeting regarding rhb with the danish health and medicines authority dkma following the positive results of the meeting the company intends to submit a marketing authorization application maa to market rhb in europe with denmark as the reference member state for the european mutual recogn pdf mar   redhill biopharma to present at the th annual roth conference telaviv israel march   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl the company or redhill an emerging israeli biopharmaceutical company focused primarily on the development and acquisition of late clinicalstage patentprotected new formulations and combinations of existing drugs today announced that dror pdf feb   redhill biopharma provides update on development progress and planned nda submission for rhb oncology support antiemetic following a successful comparative bioavailability trial the company met with the fda to discuss its planned new drug application nda filing for rhb company plans to file the rhb nda in q rhb is a proprietary extended release oncedaily oral formulation of ondansetron a leading drug for the prevention of  pdf feb   redhill biopharma reports  fourth quarter and yearend results key planned milestones for  include commencement of phase iii and phase iiiii studies with rhb crohns disease and rhb h pylori respectively and new drug application nda filings with rhb oncology support antiemetic and rhb acute migraine telaviv israel feb   globe newswire  redhill biopharma  pdf feb   redhill biopharma announces notice of allowance from the united states patent and trademark office for its cardio drug rhb rhb is a proprietary controlled release oncedaily formulation of carvedilol for the treatment of hypertension congestive heart failure and left ventricular dysfunction the expected expiration date of the us patent is  telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl  pdf feb   redhill biopharma announces date of  financial results and corporate update conference call telaviv israel feb   globe newswire  redhill biopharma ltd nasdaqrdhl taserdhl an israeli biopharmaceutical company focusing primarily on development and acquisition of late clinicalstage patentprotected new formulations and combinations of existing drugs announced that it plans to release its fy  results on tuesday pdf jan   redhill biopharma announces issuance of new us patent and provides update on rhb for treatment of crohns disease patient recruitment in an initial phase iii study is planned to commence q multisite initiation process is underway newly issued patent expires no earlier than  additional planned and required studies which include a second phase iii crohns disease trial in europe and other supplementary studies are under preparation as part pdf dec   redhill biopharma announces nasdaq listing and commencement of trading under the ticker rdhl trading on nasdaq to commence today thursday december th  following final approvals from sec and nasdaq the listing does not include capital raising as part of the registration process redhill biopharma recently completed a private placement of approximately  million telaviv israel dec   globe newsw pdf dec   redhill announces successful completion of a private placement of approximately  million pdf dec   hebrew redhill announces successful completion of a private placement of approximately  million pdf nov   redhill announces notice of allowance for a new us patent for rhb crohns pdf nov   hebrew redhill announces notice of allowance for a new us patent for rhb crohns pdf nov   redhill plans nda filing with rhb migraine following positive prenda meeting on nov th with fda pdf oct   redhill to initiate piia multiple sclerosis study with rhb following positive preclinical studies pdf oct   hebrew redhill to initiate piia multiple sclerosis study with rhb following positive preclinical studies pdf sep   redhill biopharma filed a registration statement for nasdaq listing pdf sep   hebrew redhill biopharma filed a registration statement for nasdaq listing pdf may   redhill announces successful pivotal be trial results with rhb migraine pdf may   hebrew redhill biopharma announces successful pivotal bioequivalence trial results with rhb migraine pdf apr   redhill biopharma commenced advanced clinical trial with rhb migraine pdf apr   hebrew redhill biopharma commenced advanced clinical trial with rhb migraine pdf apr   hebrew see dror ben asher ceo and gilead radays vp product development tv interview regarding rhb trial results pdf apr   redhill biopharma announces successful pivotal bioequivalence trial results with rhb prevention of nausea and vomiting pdf apr   hebrew redhill biopharma announces successful pivotal bioequivalence trial results with rhb prevention of nausea and vomiting pdf mar   redhill biopharmas rhb prevention of nausea and vomiting featured by the israeli ministry of foreign affairs pdf feb   redhill biopharmas rhb prevention of nausea and vomiting advanced clinical trial has began pdf feb   hebrew redhill biopharmas rhb prevention of nausea and vomiting advanced clinical trial has began pdf feb   redhill biopharma obtains fda ind for advanced clinical trial with rhb prevention of nausea and vomiting pdf feb   hebrew redhill biopharma obtains fda ind for advanced clinical trial with rhb prevention of nausea and vomiting pdf feb   redhill biopharma obtains a cta approval from health canada to commence an advanced trial with rhb prevention of nausea  vomiting pdf feb   hebrew redhill biopharma obtains a cta approval from health canada to commence an advanced trial with rhb prevention of nausea  vomiting pdf feb   mr gilead radays interview on israelc regarding rhb prevention of nausea  vomiting in cancer patients pdf jan   intelgenx redhills development partner in rhb migraine announces health canada approval for pivotal trial pdf nov   dr jeff lehighton presents redhill biopharma on bloomberg tv pdf nov   redhill biopharma engages with cro for potential pivotal trial with rhb prevention of nausea  vomiting in cancer patients pdf nov   hebrew redhill biopharma engages with cro for potential pivotal trial with rhb prevention of nausea  vomiting in cancer patients pdf oct   redhill biopharma appoints prof colm omorain md as lead investigator for the european phase iii trial with rhb crohns pdf oct   hebrew redhill biopharma appoints prof colm omorain md as lead investigator for the european phase iii trial with rhb crohns pdf oct   redhill biopharma appoints prof david y graham md as lead investigator for the us pivotal trial with rhb crohns pdf oct   hebrew redhill biopharma appoints prof david y graham md as lead investigator for the us pivotal trial with rhb crohns pdf sep   redhill biopharma acquires exclusive rights to a map bacterium companion diagnostic test for its rhb crohns pdf jun   intelgenx and redhill sign a binding termsheet for an antipsychotic film product pdf apr   redhill biopharma appoints advisory board headed by dr jeff leighton pdf apr   hebrew redhill biopharma appoints advisory board headed by dr jeff leighton pdf feb   redhill appoints tevas former cfo dan suesskind as director pdf feb   hebrew redhill appoints tevas former cfo dan suesskind as director pdf feb   hebrew tel aviv stock exchange ticker and isin details share and warrant pdf feb   redhill biopharma announces successful ipo on the tel aviv stock exchange pdf feb   hebrew redhill biopharma announces successful ipo on the tel aviv stock exchange pdf nov   redhill announces successful completion of m financing   times more than originally planned pdf nov   hebrew redhill announces successful completion of m financing   times more than originally planned pdf oct   intelgenx exhibits versafilm triptan rhb poster at cphl paris pdf sep   redhill biopharma raises m in a private placement tel aviv september   – redhill biopharma ltd an israeli biopharmaceutical company has completed the first part of a private placement raising  million dollars the company also reports the final closing of two transactions a codevelopment agreement and an acquisition both for late clinicalstage drugs redhill is also exp pdf aug   giaconda completes sale of  products to redhill biopharma sydney nsw  august   giaconda limited asxgia the “company” today announced that it has completed the sale of its myoconda heliconda and picoconda patents to redhill biopharma ltd “redhill” as announced in the  august  release  giaconda is receiving an upfront payment of us pdf aug   intelgenx and redhill announce definitive agreement saint laurent quebec–marketwire – aug   – intelgenx corp tsx ventureigxotcbbigxt “intelgenx” and redhill biopharma ltd an israeli corporation “redhill” today announced that they have entered into a codevelopment and commercialization agreement for intelgenx’ pdf may   scolr pharma and redhill biopharma enter into licensing agreement bothell wa may   – scolr pharma inc nyse amex ddd today announced that it has executed a licensing agreement with redhill biopharma ltd an israeli corporation redhill granting redhill the worldwide rights to market and sell ondansetron tablet formulations based on scolr’s proprietary extended delivery technology c pdf dec   egalet and redhill biopharma enter into license agreement copenhagen denmark – december nd  egalet as denmark and redhill biopharma ltd israel have entered into an exclusive license agreement that enables redhill to further develop and commercialize egalet’s proprietary program egp egp is egalet’s prolonged release formulation of the active component carvedilol th pdf subscribe to press releases press releases events  webcasts sec filings and financial information stock information analyst information corporate governance contact us investor tools email alerts subscription download library snapshot rss news feeds print share facebook google linkedin twitter email rss home  site menu  privacy  terms copyright  all rights reserved for redhill biopharma ltdcreated by catom web design redhill biopharma announces exclusive us license from entera health for commercial gi product enteragam®homemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets open in  minssp futures dow futures nasdaq futures redhill biopharma announces exclusive us license from entera health for commercial gi product enteragam®globenewswire•april  reblogsharetweetshareredhill expects to initiate us promotion of its two commerciallyavailable gastrointestinal specialty products donnatal® and enteragam® in midunder the terms of the agreement redhill will pay entera health royalties on net sales generated from the sale of enteragam® by redhilltelaviv israel april   globe newswire  redhill biopharma ltd rdhl telaviv stock exchangerdhl redhill or the company a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for gastrointestinal gi and inflammatory diseases and cancer today announced the signing of an exclusive license agreement with entera health inc entera health a privately held us company focused on the research manufacturing and commercialization of valueadded proteins and protein coproducts granting redhill the exclusive us rights to enteragam®enteragam® is a commerciallyavailable medical food intended for the dietary management of chronic diarrhea and loose stools which must be administered under medical supervision  net sales of enteragam® in the us were over  million enteragam® is a serumderived bovine immunoglobulinprotein isolate sbi with a unique mechanism of action intended to restore gut balance enteragam® has been studied for various uses such as diarrheapredominant irritable bowel syndrome ibsd inflammatory bowel disease ibd and human immunodeficiency virus hivassociated enteropathyguy goldberg redhills chief business officer said we look forward to initiating the promotion of donnatal® and enteragam® in mid we are currently in advanced stages of building redhills commercial operations in the us and are excited to complement our product portfolio with a second commercial product geared towards gastroenterologists we would like to thank our new partners at entera health and look forward to a successful longterm partnershipadi frish redhills senior vp business development and licensing said this is another important step in implementing our strategic plan of becoming a revenuegenerating gastrointestinalfocused specialty pharmaceutical company in the us we continue to pursue additional commercial product opportunities in the specialty gi area to further expand our commercial operations in parallel we continue to advance the development of our three phase iii gi products which if approved by the fda we intend to commercialize in the usaage lauridsen entera healths ceo said we are very pleased to partner with redhill to secure the continued marketing of enteragam® in the us and are confident that redhills sales team will continue to grow the value of this unique productunder the terms of the agreement redhill licensed the exclusive us rights to enteragam® for all indications for human use redhill will pay entera health tiered royalties on net sales generated from the sale of enteragam® by redhill and is not required to make any upfront or milestone payments under the terms of the agreement entera health will also grant redhill certain us rights to its fdaapproved dicyclomine hydrochloride oral solution usp  mg ml an antispasmodic and anticholinergic antimuscarinic agent indicated for the treatment of functional bowelirritable bowel syndromenumerous publications of clinical studies and retrospective chart reviews support the use of sbi in the dietary management of chronic diarrhea and loose stools the combined effect of sbi is intended to fulfill a distinctive nutritional requirement associated with various gastrointestinal conditions where chronic diarrhea or loose stools are present and normal dietary proteins alone are insufficient sbi has been shown in clinical studies to reduce loose stools and improve stool consistency as well as other symptoms such as abdominal pain bloating and urgency in patients with chronic diarrhea and loose stools several studies in patients suffering from inflammatory bowel diseases such as ulcerative colitis and crohns disease suggest that sbi improves clinical symptomatic management of patients who are not fully managed on traditional therapies sbi has also been studied in patients with fecal incontinence with chronic diarrhea in patients with celiac and nonceliac gluten sensitivity with chronic diarrhea and in additional gastrointestinal indicationsread moreno significant interactions of enteragam® with commonly prescribed medications or therapies have been reported according to entera health it is estimated that since enteragam® was introduced in  nearly  million doses of enteragam® have been administered to patients in the us with an overall adverse events rate of less than  with no serious adverse events attributed to enteragam® during postmarketing surveillancein january  redhill announced an exclusive copromotion agreement with a subsidiary of concordia international corp granting redhill certain promotional rights in the us for donnatal® a prescription oral drug used with other drugs in the treatment of irritable bowel syndrome irritable colon spastic colon mucous colitis and acute enterocolitis inflammation of the small bowelabout enteragam®enteragam® a serumderived bovine immunoglobulinprotein isolate sbi is a medical food product intended for the dietary management of chronic diarrhea and loose stools enteragam® must be administered under medical supervision enteragam® binds microbial components such as toxic substances released by bacteria that upset the intestinal environment this helps prevent them from penetrating the lining of the intestine which may contribute to chronic diarrhea and loose stools in people who have specific intestinal disorders safety informationenteragam® contains beef protein therefore patients who have an allergy to beef or any other component of enteragam® should not take this product  enteragam® has not been studied in pregnant women in women during labor and delivery or in nursing mothers  the choice to administer enteragam® during pregnancy labor and delivery or to nursing mothers is at the clinical discretion of the prescribing physicianenteragam® does not contain any milkderived ingredients such as lactose casein or whey  enteragam® is glutenfree dyefree and soyfree please see full product informationto report suspected adverse reactions contact entera health inc at entera  or the fda at fda  or wwwfdagovmedwatchabout donnatal®donnatal® phenobarbital hyoscyamine sulfate atropine sulfate scopolamine hydrobromide a prescription drug is classified as possibly effective as an adjunctive therapy in the treatment of irritable bowel syndrome irritable colon spastic colon mucous colitis and acute enterocolitis donnatal® slows the natural movements of the gut by relaxing the muscles in the stomach and intestines and acts on the brain to produce a calming effect donnatal® comes in two formulations immediate release donnatal® tablets and immediate release donnatal® elixir a fastacting liquidimportant safety informationdonnatal® is contraindicated in patients who have glaucoma obstructive uropathy obstructive disease of the gastrointestinal tract paralytic ileus unstable cardiovascular status severe ulcerative colitis myasthenia gravis hiatal hernia with reflux esophagitis or known hypersensitivity to any of the ingredients patients who are pregnant or breastfeeding or who have autonomic neuropathy hepatic or renal disease hyperthyroidism coronary heart disease congestive heart failure cardiac arrhythmias tachycardia or hypertension should notify their doctor before taking donnatal® side effects may include dryness of the mouth urinary retention blurred vision dilation of pupils rapid heartbeat loss of sense of taste headache nervousness drowsiness weakness dizziness insomnia nausea vomiting and allergic reactions which may be severefurther information including prescribing information can be found on wwwdonnatalcomplease see the following website for complete important safety information about donnatal® httpwwwdonnatalcomprofessionalsimportantsafetyinformationabout redhill biopharma ltdredhill biopharma ltd rdhl telaviv stock exchangerdhl is a specialty biopharmaceutical company headquartered in israel primarily focused on the development and commercialization of late clinicalstage proprietary orallyadministered small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer redhill has a us copromotion agreement with concordia for donnatal® a prescription oral adjunctive drug used in the treatment of ibs and acute enterocolitis as well as an exclusive license agreement with entera health for enteragam® a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools redhills clinicalstage pipeline includes i rhb  an oral combination therapy for the treatment of helicobacter pylori infection with successful results from a first phase iii study ii rhb  an oral combination therapy for the treatment of crohns disease with an ongoing first phase iii study a completed proofofconcept phase iia study for multiple sclerosis and qidp status for nontuberculous mycobacteria ntm infections iii bekinda® rhb  a oncedaily oral pill formulation of ondansetron with an ongoing phase iii study for acute gastroenteritis and gastritis and an ongoing phase ii study for ibsd iv rhb  an encapsulated bowel preparation licensed to salix pharmaceuticals ltd v yeliva® abc  a phase iistage orallyadministered firstinclass sk selective inhibitor targeting multiple oncology inflammatory and gastrointestinal indications vi mesupron  a phase iistage firstinclass orallyadministered protease inhibitor targeting pancreatic cancer and other solid tumors and vii rizaport® rhb  an oral thin film formulation of rizatriptan for acute migraines with a us nda currently under discussion with the fda and marketing authorization received in germany in october  more information about the company is available at wwwredhillbiocomthis press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  such statements may be preceded by the words intends may will plans expects anticipates projects predicts estimates aims believes hopes potential or similar words forwardlooking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties many of which are beyond the companys control and cannot be predicted or quantified and consequently actual results may differ materially from those expressed or implied by such forwardlooking statements such risks and uncertainties include without limitation risks and uncertainties associated with i the initiation timing progress and results of the companys research manufacturing preclinical studies clinical trials and other therapeutic candidate development efforts ii the companys ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials iii the extent and number of additional studies that the company may be required to conduct and the companys receipt of regulatory approvals for its therapeutic candidates and the timing of other regulatory filings approvals and feedback iv the manufacturing clinical development commercialization and market acceptance of the companys therapeutic candidates v the companys ability to successfully market donnatal® and enteragam® vi the companys ability to establish and maintain corporate collaborations vii the companys ability to acquire products approved for marketing in the us that achieve commercial success and build its own marketing and commercialization capabilities viii the interpretation of the properties and characteristics of the companys therapeutic candidates and of the results obtained with its therapeutic candidates in research preclinical studies or clinical trials ix the implementation of the companys business model strategic plans for its business and therapeutic candidates x the scope of protection the company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others xi parties from whom the company licenses its intellectual property defaulting in their obligations to the company and xii estimates of the companys expenses future revenues capital requirements and the companys needs for additional financing xiii competitive companies and technologies within the companys industry more detailed information about the company and the risk factors that may affect the realization of forwardlooking statements is set forth in the companys filings with the securities and exchange commission sec including the companys annual report on form f filed with the sec on february   all forwardlooking statements included in this press release are made only as of the date of this press release we assume no obligation to update any written or oral forwardlooking statement unless required by law  donnatal® phenobarbital hyoscyamine sulfate atropine sulfate scopolamine hydrobromide is a prescription drug classified as possibly effective as an adjunctive therapy in the treatment of irritable bowel syndrome irritable colon spastic colon mucous colitis and acute enterocolitis  for more information please see the prescribing information httpwwwdonnatalcomwpcontentuploadsriskbenefitinformationdtcrevsepdf enteragam® a serumderived bovine immunoglobulinprotein isolate sbi is a commerciallyavailable medical food intended for the dietary management of chronic diarrhea and loose stools due to specific intestinal disorders which must be administered under medical supervision see full list of publications at httpenteragamcomassetslibenteragamproductinformationpdf donnatal® phenobarbital hyoscyamine sulfate atropine sulfate scopolamine hydrobromide is a prescription drug classified as possibly effective as an adjunctive therapy in the treatment of irritable bowel syndrome irritable colon spastic colon mucous colitis and acute enterocolitis  for more information please see the prescribing information httpwwwdonnatalcomwpcontentuploadsriskbenefitinformationdtcrevsepdf for more information please see the prescribing information httpswwwaccessdatafdagovdrugsatfdadocslabelslblpdf concordia pharmaceuticals inc horgan a maas k henderson a detzel c weaver e serumderived bovine immunoglobulinprotein isolate binds to pathogenassociated molecular patterns poster presented at federation of american societies for experimental biology april   san diego ca petschow bw burnett b shaw al weaver em klein gl serumderived bovine immunoglobulinprotein isolate postulated mechanism of action for management of enteropathy clin exp gastroenterol  gasbarrini a lauritano ec garcovich m sparano l gasbarrini g new insights into the pathophysiology of ibs intestinal microflora gas production and gut motility eur rev med pharmacol sci  suppl  company contact adi frish senior vp business development  licensing redhill biopharma  adiredhillbiocomir contact us marcy nanus senior vice president the trout group  mnanustroutgroupcom this announcement is distributed by nasdaq omx corporate solutions on behalf of nasdaq omx corporate solutions clientsthe issuer of this announcement warrants that they are solely responsible for the content accuracy and originality of the information contained thereinsource redhill biopharma ltd via globenewswirehugreblogsharetweetsharerecently viewedyour list is emptywhat to read nextfj companys fj is the toyota land cruiser you really wantautoblogengineer finds pattern makes millions in stocksmoney morningsponsoredjeff bezos’ brief stint as world’s richest human ends with amazon’s secondquarter whifftechcrunchbristolmyers bmy q earnings beats estimateszackswednesday apple rumors iphone  enters trial productioninvestorplacediscover it  out of  avg by k customersdiscover cardsponsorednvidia corporation nvda stock isn’t as attractive as the companyinvestorplacetrump’s unwitting legacy could be universal health coverageyahoo financesean hannity responds to claim he ran up a  tab at trumps hotel after flying in a yearold lobster from mainebusiness insiderthis will be in everyones household by banyan hillsponsoredconsumers businesses lift us economic growth in second quarterreuterstwitter is only famous now because of president trump nyse traderyahoo finance videogdp — what you need to know in markets on fridayyahoo finance bitcoin jackpot could explode by july agora financialsponsoredrepublicans warn trump no confirmation hearing for a sessions replacement and no recess appointment eitherbusiness insiderstarbucks ceo the amazonwhole foods deal shows where retail is goingyahoo financesenate skinny repeal of obamacare falls apart on senate floor after mccain defectsdonovan  republicans and  democrats let the american people down sorry trump but all i see is one incompetent idiot in the white house who have let the american people downjoin the conversation  k investors  redhill biopharma ltd menu about redhill company profile management team board of directors advisory board products commercial products donnatal® enteragam® development pipeline pipeline overview talicia™ h pylori rhb giinflammation crohns disease multiple sclerosis rheumatoid arthritis bekinda® gi gastroenteritis  gastritis ibsd rhb gi yeliva® oncology mesupron oncology rizaport® migraine expanded access program partnering investors press releases events  webcasts sec filings and financial information stock information analyst information corporate governance contact us news      contact careers homeinvestors investors corporate presentationview all redhill biopharma corporate presentation  july  jul   press releasesview all redhill biopharma reports  second quarter financial results jul   download pdf   kb redhill biopharma to host second quarter  financial results conference call on july   jul   download pdf   kb events  webcastsview all rodman  renshaw th annual global investment conference sep   location the lotte new york palace ny cantor fitzgerald global healthcare conference sep   location intercontinental new york barclay hotel ny press releases events  webcasts sec filings and financial information stock information analyst information corporate governance contact us investor tools email alerts subscription download library snapshot rss news feeds print share facebook google linkedin twitter email rss home  site menu  privacy  terms copyright  all rights reserved for redhill biopharma ltdcreated by catom web design